<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        10-5251-20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2020
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        CITAROX 1000MG VIAL
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        GEMCITABINE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        1000
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Powder for solution for infusion
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        25
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        147.85
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="S.C Sindan pharma SRL" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            S.C Sindan pharma SRL
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 2096]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Boston Oncology Arabia
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Boston Oncology Arabia
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L01BC05 
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Citarox&nbsp;belongs to a group of medicines called &ldquo;cytotoxics&rdquo;. These medicines&nbsp;kill dividing cells, including cancer cells.</p><p>Citarox may be given alone or in combination with other anti-cancer medicines, depending on the type of cancer.</p><p>Citarox is used in the treatment of the following types of cancer:</p><ul><li><p>- &nbsp;non-small cell lung cancer (NSCLC), alone or together with cisplatin</p></li><li><p>- &nbsp;pancreatic cancer.</p></li><li><p>- &nbsp;breast cancer, together with paclitaxe l.</p></li><li><p>- &nbsp;ovarian cancer, together with carboplatin.</p></li><li><p>- &nbsp;bladder cancer, together with cisplatin.</p></li></ul>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not take Citarox:</p><ul><li><p>- &nbsp;if you are allergic to gemcitabine or any of the other ingredients of this medicine (listed in section 6).</p></li><li><p>- &nbsp;if you are breast-feeding</p><p>Warnings and precautions</p><p>Before the first infusion you will have samples of your blood taken to evaluate if you have sufficient kidney and liver function. Before each infusion you will have samples of your blood taken to evaluate if you have enough blood cells to receive /.../. Your doctor may decide to change the dose or delay treating you depending on your general condition and if your blood cell counts are too low. Periodically you will have samples of your blood taken to evaluate your kidney and liver function.</p></li></ul><p>Talk to your doctor before using Citarox if:</p><ul><li><p>- &nbsp;you have, or have previously had liver disease, heart disease, vascular disease or problems with</p><p>your kidneys</p></li><li><p>- &nbsp;you have recently had, or are going to have radiotherapy</p></li><li><p>- &nbsp;you have been vaccinated recently</p></li><li><p>- &nbsp;you develop breathing difficulties or feel very weak and are very pale (may be a sign of kidney</p><p>failure or problems with your lungs).</p></li><li><p>- &nbsp;during this treatment with this medicine you experience headaches, confusion, seizures (fits),</p><p>visual disturbances or changes in vision, call your doctor right away. This could be a very rare</p><p>nervous system side effect named posterior reversible encephalopathy syndrome.</p></li><li><p>- &nbsp;you develop generalised swelling, shortness of breath or weight gain as these may be a sign of</p><p>fluid leaking from your blood vessels into the tissues.</p><p><u><strong>Children and adolescents</strong></u></p><p>This medicinal product is not recommended for use in children under 18 years of age due to insufficient data on safety and efficacy.</p><p><strong><u>Other medicines and Citarox</u></strong></p><p>Tell your doctor or hospital pharmacist if you are taking, have recently taken or might take any other medicines, including vaccinations and medicines obtained without a prescription; or if you have recently undergone radiotherapy or are going to have radiotherapy.</p><p><u><strong>Pregnancy, breast-feeding and fertility</strong></u><br />Pregnancy<br />If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine. The use of /.../ should be avoided during pregnancy. Your doctor will discuss with you the potential risk of taking /.../ during pregnancy.</p><p>Brest-feeding</p><p>If you are breast-feeding, tell your doctor.<br />You must discontinue breast-feeding during /.../ treatment.</p><p>Fertility</p><p>Men are advised not to father a child during and up to 6 months following treatment with /.../. If you would like to father a child during the treatment or in the 6 months following treatment, seek advice from your doctor or pharmacist. You may want to seek counselling on sperm storage before starting your therapy.</p><p><strong>Driving and using machines</strong></p><p>/.../ may make you feel sleepy, particularly if you have consumed any alcohol. Do not drive a car or use machinery until you are sure that /.../ treatment has not made you feel sleepy.</p><p>/.../ contains sodium<br />Citarox contains 3.56 mg (&lt; 1 mmol) of sodium in each 200 mg vial and 17.81 mg (&lt; 1 mmol) sodium in each 1 g vial and 35.62 mg (1.54 mmol) sodium in each 2 g vial. To be taken into consideration by patients on a controlled sodium diet.</p></li></ul>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The recommended dose of Citarox is 1000-1250 mg for every square metre of your body&rsquo;s surface&nbsp;area. Your height and weight are measured to work out the surface area of your body. Your doctor will use this body surface area to work out the right dose for you. This dosage may be adjusted, or treatment may be delayed depending on your blood cell counts and on your general condition.</p><p>How frequently you receive your Citarox infusion depends on the type of cancer that you are being treated for.</p><p>A hospital pharmacist or doctor will have dissolved the Citarox powder before it is given to you.</p><p>You will always receive Citarox by infusion into one of your veins. The infusion will last approximately&nbsp;30 minutes.</p><p>If you have further questions on the use of this product ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>You must contact your doctor immediately if you notice any of the following:</p><p>- &nbsp;Fever or infection (common, may affect up to 1 in 10 people): if you have a temperature of 38oC or greater, sweating or other signs of infection (since you might have less white blood cells than normal which is very common).</p><p>- &nbsp;Irregular heart rate (arrhythmia) (uncommon, may affect up to 1 in 100 people).</p><p>- &nbsp;Pain, redness, swelling or sores in your mouth (common, may affect up to 1 in 10 people).</p><p>- &nbsp;Allergic reactions: if you develop skin rash (very common, may affect more than 1 in 10&nbsp;people) / itching (common, may affect up to 1 in 10 people), or fever (very common, may affect&nbsp;more than 1 in 10 people).</p><p>- &nbsp;Anaphylactic reaction (severe hypersensitivity/ allergic reaction): skin rash including red itchy&nbsp;skin, swelling of the hands, feet, ankles, face, lips, mouth or throat (which may cause difficulty in swallowing or breathing), wheezing, fast beating heart (tachycardia) and you may feel you are going to faint (a spontaneous loss of consciousness caused by insufficient blood to the brain) (very rare (may affect up to 1 in 10,000 people).</p><p>- &nbsp;Tiredness, feeling faint, becoming easily breathless or if you look pale (since you might have less haemoglobin than normal which is very common, may affect more than 1 in 10 people).</p><p>- &nbsp;Bleeding from the gums, nose or mouth or any bleeding that would not stop, reddish or pinkish urine, unexpected bruising (since you might have less platelets than normal which is very common, may affect more than 1 in 10 people).</p><p>- &nbsp;Difficulty breathing (it is very common to have mild breathing difficulty soon after the /.../ infusion which soon passes, however uncommonly or rarely there can be more severe lung problems).</p><p>- &nbsp;Heart attack (myocardial infarction) (rare (may affect up to 1 in 1,000 people))</p><p>- &nbsp;Haemolytic uraemic syndrome: extreme tiredness and weakness, purpura or small areas of&nbsp;bleeding in the skin (bruises), acute renal failure (low urine output /or no urine output), and&nbsp;signs of infection. It may be fatal (uncommon (may affect up to 1 in 100 people)).</p><p>- &nbsp;Potentially life-threatening cutaneous reactions (Toxic epidermal necrolysis (TEN), Stevens-&nbsp;Johnson Syndrome (SJS)): severe rash with itching, blistering or peeling of the skin. Skin rashes are often accompanied by flu-like symptoms (very rare, may affect up to 1 in 10,000 people).</p><p>- &nbsp;Headaches with changes in vision, confusion, seizures or fits (posterior reversible encephalopathy syndrome) (very rare, may affect up to 1 in 10,000 people).</p><p>- &nbsp;Generalised swelling, shortness of breath or weight gain, since you may have fluid leakage from your blood vessels into the tissues (capillary leak syndrome) (very rare, may affect up to 1 in 10,000 people).</p><p><strong>Other side effects with /.../ may include:<br />Very common side effects (may affect more than 1 in 10 people)</strong></p><p>Low haemoglobin level (anaemia) Low white blood cells<br />Low platelet count<br />Difficulty breathing<br />Vomiting<br />Nausea<br />Skin rash- allergic skin rash, frequently itchy<br />Hair loss<br />Liver problems: found through abnormal blood test results Blood in urine<br />Abnormal urine tests: protein in urine<br />Flu like symptoms including fever<br />Oedema (swelling of ankles, fingers, feet, face)</p><p><strong>Common side effects (may affect up to 1 in 10 people)</strong></p><p>Fever accompanied by low white blood cell count (febrile neutropaenia) Anorexia (poor appetite)<br />Headache<br />Insomnia<br />Sleepiness<br />Cough<br />Runny nose<br />Constipation<br />Diarrhoea<br />Pain, redness, swelling or sores in the mouth Itching<br />Sweating Muscle pain Back pain Fever Weakness Chills</p><p><strong>Uncommon side effects (may affect up to 1 in 100 people)</strong></p><p>Stroke<br />Irregular heart beat (arrhythmia)<br />Heart failure<br />Interstitial pneumonitis (scarring of the air sacs of the lung)<br />Spasm of the airways (wheeze)<br />Abnormal chest X ray/scan (scarring of the lungs)<br />Serious liver damage, including liver failure which could be life-threatening<br />Kidney failure<br />Haemolytic uraemic syndrome (extreme tiredness and weakness, purpura or small areas of bleeding in the skin (bruises), acute renal failure (low urine output /or no urine output), and signs of infection, it may be fatal)</p><p><strong>Rare side effects (may affect up to 1 in 1,000 people)</strong></p><p>Heart attack (myocardial infarction) Low blood pressure<br />Gangrene of fingers or toes<br />Fluid in the lungs<br />Adult Respiratory Distress Syndrome (severe lung inflammation causing respiratory failure)<br />Skin scaling, ulceration or blister formation<br />Injection site reactions<br />Radiation toxicity- scarring of the air sacs of the lung associated with radiation therapy<br />Radiation recall-(a skin rash like severe sunburn) which can occur on skin that has previously been exposed to radiotherapy.</p><p><strong>Very rare side effects (may affect up to 1 in 10,000 people)</strong></p><p>Increased platelet count<br />Anaphylactic reaction (severe hypersensitivity/ allergic reaction)<br />Ischemic colitis (inflammation of the lining of the large bowel, caused by reduced blood supply) Sloughing of skin and severe skin blistering (Toxic epidermal necrolysis, Stevens-Johnson Syndrome).<br />Capillary leak syndrome (leakage of fluid from the blood vessels into the tissue)<br />Posterior reversible encephalopathy syndrome (a neurologic condition with symptoms including seizures, headache, confusion and changes in vision.</p><p>You might have any of these symptoms and/or conditions.<br />You must tell your doctor as soon as possible when you start experiencing any of these side effects.</p><p><strong><u>Reporting of side effects</u></strong></p><p>If you get any side effects, talk to your doctor, pharmacist or nurse.<br />This includes any possible side effects not listed in this leaflet.<br />You can also report side effects directly via&nbsp;the national reporting system listed in&nbsp;Appendix V.<br />By reporting side effects you can help provide more information on the safety of this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>Unopened container</p><p>Do not refrigerate or freeze.</p><p>Opened container</p><p>After opening, the contents should be reconstituted, and if appropriate further diluted, and used immediately. Reconstituted solutions should not be refrigerated, as crystallisation may occur.</p><p>Do not use this medicine after the expiry date which is stated on the label and carton. The expiry date refers to the last day of that month.</p><p>Do not use this medicine if you notice any signs of particles.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is gemcitabine (as hydrochloride). After reconstitution one ml of Citarox contains 38 mg gemcitabine. One vial Citarox contains 200 mg, 1 g or 2 g<br />gemcitabine.</p><p>The other ingredients are mannitol E421, sodium acetate trihydrate and sodium hydroxide 1 N (for pH adjustment)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Citarox powder for solution for infusion is a white to off-white compact aggregate powder. After reconstitution in 0.9% sodium chloride solution, the solution is clear to pale opalescent and colourless to pale yellow.
Citarox is in colourless glass vials with bromobutylic rubber stopper and sealed with aluminium seals with plastic caps. Each vial will be packed with or without a protective plastic overwrap.
Pack sizes
One vial containing 200 mg gemcitabine. 
One vial containing 1 g gemcitabine. One vial containing 2 g gemcitabine.
Not all pack sizes may be marketed.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Tadawi Biomedical company</strong><br />Olaya st, Riyadh Saudi Arabia<br />Manufacturers<br />S.C. Sindan-Pharma S.R.L. 11 Ion Mihalache Blvd.</p><p><strong>Bucharest, 011171 Romania</strong><br />Actavis Italy S.p.A.&nbsp;&ndash;&nbsp;Nerviano Plant Viale Pasteur 10<br />20014 Nerviano (MI)<br />Italy</p><p><strong>Secondary packaging</strong><br />Tadawi Biomedical company<br />Olaya st, Riyadh Saudi Arabia</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                2019
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">ينتمي&nbsp;<strong>سيتاروكس</strong>&nbsp;مسحوق للحل والتسريب&nbsp;إلى مجموعة الأدوية المسماة &quot;السامة الخلوية&quot;. هذه الأدوية تقتل الخلايا المنقسمة، بما في ذلك الخلايا السرطانية.</p><p dir="RTL">يمكن أن يُعطى&nbsp;سيتاروكس&nbsp;مسحوق للحل والتسريب&nbsp;بمفرده أو بالمشاركة مع الأدوية الأخرى المضادة للسرطان، اعتماداً على نوع السرطان.</p><p dir="RTL">يُستخدم&nbsp;سيتاروكس&nbsp;مسحوق للحل والتسريب&nbsp;لمعالجة أنواع السرطان التالية:</p><p dir="RTL">&bull; سرطان الرئة ذو الخلايا غير الصغيرة (NSCLC)، بمفرده أو بالمشاركة مع سيسبلاتين.</p><p dir="RTL">&bull; سرطان البنكرياس.</p><p dir="RTL">&bull; سرطان الثدي، بالمشاركة مع باكليتاكسيل.</p><p dir="RTL">&bull; سرطان المبيض، بالمشاركة مع كاربوبلاتين.</p><p dir="RTL">&bull; سرطان المثانة، بالمشاركة مع سيسبلاتين.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>يجب أن لا يُعطى لك&nbsp;سيتاروكس مسحوق للحل والتسريب:</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">- إذا كنت تتحسس (فرط حساسية) من&nbsp;سيتاروكس&nbsp;أو من أي المكونات الأخرى لدواء&nbsp;سيتاروكس&nbsp;مسحوق للحل والتسريب&nbsp;(المدرجة في القسم 6).</p><p dir="RTL">- إذا كنتِ تُرضعينَ من ثدييكِ.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يجب اتخاذ عناية خاصة مع&nbsp;سيتاروكس مسحوق للحل والتسريب:</strong></p><p dir="RTL">قبل التسريب الأول سوف يؤخذ من دمك عينات لتقييم ما إذا كان لديك ما يكفي من وظيفة كلٍّ من الكلى والكبد. وقبل كل تسريب سوف يؤخذ من دمك عينات لتقييم ما إذا كان لديك ما يكفي من خلايا الدم لتلقي سيتاروكس مسحوق للحل والتسريب. قد يقرر طبيبك تغيير الجرعة أو تأخير علاجك اعتماداً على حالتك العامة وإذا كان تعداد خلايا الدم لديك منخفض جداً. وبشكل دوري سيؤخذ منك عينات من الدم لتقييم وظيفة كلّاً من الكلى والكبد.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يرجى إخبار طبيبك إذا:</strong></p><p dir="RTL">&bull; كان لديك حالياً، أو كان عندك سابقاً مرض كبد, مرض قلب أو أمراض أوعية دموية.</p><p dir="RTL">&bull; كان لديك مؤخراً، أو سيكون لديك معالجة شعاعية.</p><p dir="RTL">&bull; تم تلقيحك مؤخراً.</p><p dir="RTL">&bull; عانيت من صعوبات في التنفس أو شعرت بضعف شديد وأنت شاحب اللون جداً (قد تكون علامة على الفشل الكلوي).</p><p dir="RTL">&bull; عانيت من تورُّم عام. ضيق في التنفس أو زيادة الوزن، لأن ذلك قد يكون علامة على تسرب السوائل من الأوعية الدموية الصغيرة إلى داخل الأنسجة، وأعراض حالة خطيرة تسمى متلازمة التسرب الشعري (CLS).</p><p dir="RTL">&bull; حصل معك أثناء المعالجة بهذا الدواء أعراض مثل صداع مع إرتباك, نوبات أو تغيرات في الرؤية. يجب عليك الاتصال بطبيبك على الفور، لأن ذلك قد يكون من التأثيرات الجانبية النادرة جداً للجهاز العصبي والمسماة متلازمة إعتلال الدماغ الخلفي العكسي (PRES).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تناول أدوية أخرى</strong></p><p dir="RTL">يرجى إخبار طبيبك أو صيدلي المستشفى إذا كنت تتناول أو قد تناولت مؤخراً أية أدوية أخرى، بما في ذلك اللقاحات والأدوية التي تحصل عليها بدون وصفة طبية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية</strong></p><p dir="RTL">إذا كنتِ حاملاً، أو تظنينَ بأنكِ ستُصبحينَ حاملاً، أخبري طبيبكِ. يجب تجنب استخدام&nbsp;سيتاروكس&nbsp;مسحوق للحل والتسريب&nbsp;أثناء فترة الحمل. سيناقش طبيبكِ معكِ المخاطر المحتملة من تناول&nbsp;سيتاروكس&nbsp;مسحوق للحل والتسريب&nbsp;أثناء فترة الحمل.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الخصوبة</strong></p><p dir="RTL">يُنصح الرجال بعدم السعي وراء إنجاب طفل خلال المعالجة ولفترة تصل إلى 6 أشهر بعد المعالجة بدواء&nbsp;سيتاروكس&nbsp;مسحوق للحل والتسريب. إذا كنت ترغب بإنجاب طفلٍ أثناء المعالجة أو في فترة الـ 6 أشهر بعدها, أطلب مشورة طبيبك أو الصيدلي. قد ترغب بطلب الاستشارة بشأن تخزين الحيوانات المنوية قبل بدء المعالجة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا كنتِ تُرضعينَ طبيعياً، أخبري طبيبكِ.</strong></p><p dir="RTL">يجب عليكِ التوقف عن الرضاعة الطبيعية خلال المعالجة بدواء&nbsp;سيتاروكس&nbsp;مسحوق للحل والتسريب.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">قد يجعلك&nbsp;سيتاروكس&nbsp;مسحوق للحل والتسريب&nbsp;تشعر بالنعاس، وخاصة إذا كنت قد تعاطيت أي كحول. لا تقود السيارة أو تستخدم الآلات حتى تكون متأكداً من أن المعالجة بدواء&nbsp;سيتاروكس&nbsp;مسحوق للحل والتسريب&nbsp;لا تجعلك تشعر بالنعاس.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>معلومات هامة عن بعض مكونات دواء&nbsp;سيتاروكس مسحوق للحل والتسريب</strong></p><p dir="RTL">يحتوي&nbsp;سيتاروكس&nbsp;مسحوق للحل والتسريب&nbsp;17,5 ملغ (&lt;1 مليمول) من الصوديوم في كل قارورة من 1000 ملغ. ينبغي أخذ ذلك بعين الإعتبار من قبل المرضى الذين يتبعون حمية الصوديوم.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">الجرعة المعتادة من&nbsp;سيتاروكس&nbsp;هي 1000- 1250 ملغ لكل متر مربع من مساحة سطح جسمك. يتم قياس طولك ووزنك لاستنباط مساحة سطح جسمك. سوف یستخدم طبیبك مساحة سطح الجسم ھذه لتحدید الجرعة المناسبة لك. قد يتم تعديل هذه الجرعة، أو قد تؤخر المعالجة تبعاً لتعداد خلايا دمك ولحالتك العامة.</p><p dir="RTL">إن عدد المرات التي ستتلقى فيها&nbsp;سيتاروكس&nbsp;مسحوق للحل والتسريب&nbsp;يعتمد على نوع السرطان الذي أنت تُعالج لأجله.</p><p dir="RTL">سيقوم صيدلي المستشفى أو الطبيب في المستشفى بحل&nbsp;سيتاروكس&nbsp;مسحوق&nbsp;قبل إعطائه لك.</p><p dir="RTL">ستتلقى دائماً&nbsp;سيتاروكس&nbsp;بداخل أحد أوردتك. وسيستمر التسريب حوالي 30 دقيقة.</p><p dir="RTL">إذا كان لديك أسئلة أخرى حول استخدام هذا الدواء، اسأل طبيبك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية، يمكن أن يُسبب&nbsp;سيتاروكس&nbsp;مسحوق للحل والتسريب&nbsp;تأثيرات جانبية، وإن كانت لا تحدث لكل شخص.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لقد تم تحديد تكرار التأثيرات الجانبية الملاحظة كما يلي:</p><p dir="RTL">&bull; شائعة جداً:&nbsp;&nbsp;&nbsp;&nbsp;تؤثر في أكثر من 1 مُستخدِم من كل 10.</p><p dir="RTL">&bull; شائعة:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;تؤثر في 1 إلى 10 مُستخدِمين من كل 100.</p><p dir="RTL">&bull; غير شائعة:&nbsp;&nbsp;&nbsp;&nbsp;تؤثر في 1 إلى 10 مُستخدِمين من كل 1000.</p><p dir="RTL">&bull; نادرة:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;تؤثر في 1 إلى 10 مُستخدِمين من كل 10,000.</p><p dir="RTL">&bull; نادرة جداً:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;تؤثر في أقل من 1 مُستخدم من كل 10,000.</p><p dir="RTL">&bull; غير معروفة:&nbsp;&nbsp;لا يمكن تقدير تكرارها من البيانات المتاحة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يجب عليك الاتصال بطبيبك فوراً إذا لاحظت أي ممّا يلي:</strong></p><p dir="RTL">&bull; حمى أو عدوى (شائعة): إذا كانت درجة حرارتك 38 مئوية أو أكثر، تعرُّق أو علامات عدوى أخرى (حيث يمكن أن تكون لديك خلايا الدم البيضاء أقل من المعتاد وهذا أمر شائع جداً).</p><p dir="RTL">&bull; عدم انتظام ضربات القلب (إيقاع غير منتظم) (التكرار غير معروف).</p><p dir="RTL">&bull; ألم، إحمرار، تورُّم أو تقرحات في فمك (شائع).</p><p dir="RTL">&bull; ردود فعل تحسسية: إذا واجهت طفح جلدي (شائع جداً) / حكة (شائعة) أو حمى (شائعة جداً).</p><p dir="RTL">&bull; تعب، شعور بالإغماء، أصبحت تلهث بسهولة أو إذا كنت تبدو شاحب اللون (لأن الهيموغلوبين عندك أقل من المعتاد وهذا شائع جداً).</p><p dir="RTL">&bull; نزف من اللثة, الأنف أو الفم أو أي نزيف آخر لا يتوقف، بول مُحمر أو وردي، کدمات غير&nbsp;متوقعة (قد تكون الصفيحات الدموية لديك أقل من المعتاد وهذا شائع جداً).</p><p dir="RTL">&bull; صعوبة التنفس (من الشائع جداً حصول صعوبة خفيفة في التنفس فوراً بعد حقن&nbsp;سيتاروكس&nbsp;والتي تتلاشى حالاً، بينما من غير الشائع أو النادر ما يكون هناك مشاكل في الرئة أكثر شدة).</p><p dir="RTL">&bull; تورُّم عام، ضيق في التنفس أو زيادة الوزن، حيث قد يكون لديك تسرب سوائل من الأوعية الدموية الصغيرة إلى داخل الأنسجة (متلازمة تسرب الشعيرات الدموية) (نادرة جداً).</p><p dir="RTL">&bull; صداع مع تغيرات في الرؤية، إرتباك، نوبات (متلازمة إعتلال الدماغ الخلفي العكسي) (نادرة جداً).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>التأثيرات الجانبية المترافقة مع&nbsp;سيتاروكس مسحوق للحل والتسريب&nbsp;قد تشمل ما يلي:</strong></p><p dir="RTL"><strong>تأثيرات جانبية شائعة جداً</strong></p><p dir="RTL">انخفاض مستوى الهيموغلوبين (فقر الدم)</p><p dir="RTL">انخفاض خلايا الدم البيضاء</p><p dir="RTL">انخفاض تعداد الصفيحات الدموية</p><p dir="RTL">صعوبة التنفس</p><p dir="RTL">إقياء</p><p dir="RTL">غثيان</p><p dir="RTL">طفح جلد- طفح جلد تحسسي، أحياناً مع حكة</p><p dir="RTL">تساقط الشعر</p><p dir="RTL">مشاكل الكبد: وُجدت من خلال نتائج فحوص الدم غير الإعتيادية</p><p dir="RTL">دم في البول</p><p dir="RTL">فحوص بول غير إعتيادية: بروتين في البول</p><p dir="RTL">أعراض شبيهة بالأنفلونزا بما في ذلك الحمى</p><p dir="RTL">وذمة (تورُّم الكاحلين, الأصابع, القدمين, الوجه)</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تأثيرات جانبية شائعة</strong></p><p dir="RTL">حمى مترافقة بانخفاض تعداد خلايا الدم البيضاء (حمّى قلة العِدلات)</p><p dir="RTL">فقدان شهية (ضعف الشهية)</p><p dir="RTL">صداع</p><p dir="RTL">أرق</p><p dir="RTL">نعاس</p><p dir="RTL">سعال</p><p dir="RTL">سيلان أنف</p><p dir="RTL">إمساك</p><p dir="RTL">إسهال</p><p dir="RTL">ألم، إحمرار، تورُّم أو قروح في الفم</p><p dir="RTL">حكة</p><p dir="RTL">تعرق</p><p dir="RTL">ألم عضلات</p><p dir="RTL">ألم الظهر</p><p dir="RTL">حمى</p><p dir="RTL">ضعف</p><p dir="RTL">قشعريرة (بردية)</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تأثيرات جانبية غير شائعة</strong></p><p dir="RTL">التهاب رئوي خلالي (تندب الأكياس الهوائية للرئة)</p><p dir="RTL">تشنج الشعب الهوائية (أزيز)</p><p dir="RTL">أشعة سينية / تخطيط صدر غير إعتيادي (تندب الرئتين)</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تأثيرات جانبية نادرة</strong></p><p dir="RTL">نوبة قلبية (إحتشاء عضلة القلب)</p><p dir="RTL">ضغط دم منخفض</p><p dir="RTL">تقشر الجلد، تقرح أو تشكل بثرات</p><p dir="RTL">تفاعلات في موقع الحقن</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تأثيرات جانبية نادرة جدا</strong></p><p dir="RTL">تزايد عدد الصفيحات الدموية</p><p dir="RTL">رد فعل تحسسي (فرط حساسية شديد / تفاعلات تحسسية)</p><p dir="RTL">تخثر الجلد وتبثر جلدي شديد</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تأثيرات جانبية غير معروفة التكرار</strong></p><p dir="RTL">ضربات قلب غير طبيعية (إيقاع غير منتظم)</p><p dir="RTL">متلازمة الضائقة التنفسية لدى الكبار (التهاب الرئة الحاد المسبب للفشل التنفسي)</p><p dir="RTL">تكرار الإشعاع - (طفح جلدي شبيه حروق الشمس الشديدة) التي يمكن أن تحدث على الجلد الذي سبق أن تعرض للمعالجة الشعاعية.</p><p dir="RTL">سائل في الرئتين</p><p dir="RTL">سمية الإشعاع - تندب الأكياس الهوائية في الرئة مترافق مع المعالجة الشعاعية</p><p dir="RTL">التهاب قولون إقفاري (التهاب بطانة الأمعاء الغليظة، ناجمة عن انخفاض تدفق الدم)</p><p dir="RTL">فشل القلب</p><p dir="RTL">فشل الكلى</p><p dir="RTL">غرغرينا في أصابع اليدين أو أصابع القدم</p><p dir="RTL">تلف كبدي خطير، بما في ذلك فشل الكبد</p><p dir="RTL">سكتة دماغية</p><p dir="RTL">يمكن أن يكون لديك أيّاً من هذه الأعراض و/ أو الحالات. يجب عليك إخبار طبيبك بالسرعة الممكنة عندما تبدأ بالمعاناة من أي من هذه التأثيرات الجانبية.</p><p dir="RTL"><em>&nbsp;</em></p><p dir="RTL"><strong>الإبلاغ عن التأثيرات الجانبية</strong></p><p dir="RTL">إذا عانيت من أية تأثيرات جانبية تَحدَّث إلى طبيبك أو الصيدلي. ويشمل ذلك أية تأثيرات جانبية محتملة غير مدرجة في هذه النشرة. فمن خلال إبلاغك عن التأثيرات الجانبية يمكنك المساعدة بتوفير المزيد من المعلومات حول سلامة الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يُحفظ بعيداً عن متناول ورؤية الأطفال.</p><p dir="RTL">لا تستخدم&nbsp;سيتاروكس&nbsp;مسحوق للحل والتسريب&nbsp;بعد تاريخ إنتهاء الصلاحية، المذكور على العلبة والقارورة.</p><p dir="RTL">يشير تاريخ إنتهاء الصلاحية إلى آخر يوم من ذلك الشهر.</p><p dir="RTL">القارورة غير المفتوحة: لا يتطلب هذا المُنتج الطبي أية شروط تخزين خاصة.</p><p dir="RTL">إعادة التشكيل: يجب استخدام المُنتج على الفور. وعندما يُحضَّر وفقاً للتوجيهات، فإن الثبات الكيميائي والفيزيائي لاستخدام محاليل&nbsp;سيتاروكس&nbsp;المُعاد تشكيلها والمُوصى بها هو 24 ساعة بدرجة حرارة 25 مئوية. ويمكن القيام بمزيد من التخفيف من قبل مُقدم الرعاية الصحية. ويجب عدم تبريد محاليل&nbsp;سيتاروكس&nbsp;المعاد تشكيلها، حيث قد يحدث التبلر.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المادة الفعالة هي جيمسيتابين. كل قارورة تحتوي على 200، 1000 ملغ أو 2000 ملغ من جيمسيتابين (بشكل هايدروكلورايد جيمسيتابين).</p><p dir="RTL">المكونات الأخرى هي مانيتول (E421)، خلات الصوديوم، حمض الهايدروكلوريك وهايدروكسيد الصوديوم.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>سيتاروكس</strong>&nbsp;مسحوق للحل والتسريب&nbsp;أبيض إلى قريب من البياض، للحل والتسريب في قارورة. كل قارورة تحتوي على 200 ملغ، 1000 ملغ أو 2000 ملغ من&nbsp;سيتاروكس. وتحتوي كل عبوة من&nbsp;سيتاروكس&nbsp;مسحوق للحل والتسريب&nbsp;على قارورة واحدة.</p><p dir="RTL">وتباع القوارير 200 ملغ، 1غ و 2غ بشكل منفصل بعبوات إفرادية.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">شركة تداوي الطبية الحيوية شارع العليا ,</p><p dir="RTL">الرياض</p><p dir="RTL">السعودية العربية</p><p dir="RTL"><strong>الصانعون:</strong></p><p dir="RTL">أكتافيس إيطاليا س.ب.أ.</p><p dir="RTL">نيرفيانو بلانت</p><p dir="RTL">فيا باستور 10</p><p dir="RTL">20014 نيرفيانو (م آي), إيطاليا</p><p dir="RTL">أو</p><p dir="RTL">س.سي. سيندان-فارما س.ر.ل.</p><p dir="RTL">11 أيون شارع ميهالاشي 011171 بوخارست</p><p dir="RTL">ؤومانيا</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            XXXX
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Citarox 38 mg/ml powder for solution for infusion
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                One ml of the reconstituted solution for infusion (see section 6.6) contains 38 mg gemcitabine (as hydrochloride).

200 mg vial:
Each vial contains 200 mg of gemcitabine (as hydrochloride).
Contains approximately 0.15 mmol (3.56 mg) sodium per 200 mg vial.

1g vial:
Each vial contains 1 g of gemcitabine (as hydrochloride).
Contains approximately 0.77 mmol (17.81 mg) sodium per 1 g vial.

2g vial:
Each vial contains 2 g of gemcitabine (as hydrochloride)
Contains approximately 1.54 mmol (35.62 mg) sodium per 2 g vial. For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Powder for solution for infusion.

White or almost white compact aggregate. After reconstitution in sodium chloride 0.9% the solution is clear to pale opalescent and colourless to pale yellow.

The pH of the reconstituted solution in sodium chloride 0.9% solution is 3.0 ± 0.3.

The osmolarity of the reconstituted solution (38 mg/ml of gemcitabine (as hydrochloride) in sodium chloride 0.9% solution) is 775 mOsm/l.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>&nbsp;</strong>Gemcitabine&nbsp;is&nbsp;indicated&nbsp;for&nbsp;the&nbsp;treatment&nbsp;of&nbsp;locally&nbsp;advanced&nbsp;or&nbsp;metastatic bladder&nbsp;cancer&nbsp;in combination with cisplatin.</p><p>Gemcitabine&nbsp;is&nbsp;indicated&nbsp;for&nbsp;treatment&nbsp;of&nbsp;patients&nbsp;with&nbsp;locally&nbsp;advanced&nbsp;or&nbsp;metastatic adenocarcinoma&nbsp;of the pancreas.</p><p>Gemcitabine,&nbsp;in&nbsp;combination&nbsp;with&nbsp;cisplatin&nbsp;is&nbsp;indicated&nbsp;as&nbsp;first&nbsp;line&nbsp;treatment&nbsp;of&nbsp;patients&nbsp;with&nbsp;locally advanced or metastatic&nbsp;non-small cell&nbsp;lung cancer (NSCLC). Gemcitabine&nbsp;monotherapy can be considered in elderly patients or those with performance&nbsp;status 2.</p><p>Gemcitabine&nbsp;is&nbsp;indicated&nbsp;for&nbsp;the&nbsp;treatment&nbsp;of&nbsp;patients&nbsp;with&nbsp;locally&nbsp;advanced&nbsp;or&nbsp;metastatic epithelial ovarian carcinoma,&nbsp;in&nbsp;combination with&nbsp;carboplatin, in&nbsp;patients with relapsed disease following a recurrence-free interval&nbsp;of at least 6&nbsp;months after platinum-based, first-line therapy.</p><p>Gemcitabine,&nbsp;in&nbsp;combination with paclitaxel, is indicated for the treatment of patients with unresectable,locally recurrent or metastatic breast&nbsp;cancer&nbsp;who have relapsed following adjuvant/neoadjuvant&nbsp;chemotherapy.Prior&nbsp;chemotherapy&nbsp;should&nbsp;have&nbsp;included&nbsp;an&nbsp;anthracycline unless clinically contraindicated.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Gemcitabine&nbsp;should&nbsp;only&nbsp;be&nbsp;prescribed&nbsp;by&nbsp;a&nbsp;physician&nbsp;qualified in&nbsp;the&nbsp;use&nbsp;of&nbsp;anti-cancer&nbsp;chemotherapy.</p><p><u>Posology</u></p><p><u>Bladder&nbsp;cancer</u></p><p><em>Combination&nbsp;use &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</em></p><p>The&nbsp;recommended dose&nbsp;for&nbsp;gemcitabine&nbsp;is&nbsp;1000&nbsp;mg/m&nbsp;,&nbsp;given&nbsp;by&nbsp;30-minute&nbsp;infusion.&nbsp;The&nbsp;dose&nbsp;should&nbsp;be&nbsp;given&nbsp;on&nbsp;Days&nbsp;1,&nbsp;8&nbsp;and&nbsp;15&nbsp;of&nbsp;each&nbsp;28-day&nbsp;cycle in&nbsp;combination with&nbsp;cisplatin.&nbsp;Cisplatin&nbsp;is&nbsp;given&nbsp;at&nbsp;a&nbsp;recommended&nbsp;dose&nbsp;of&nbsp;70&nbsp;mg/m2&nbsp;on&nbsp;Day&nbsp;1&nbsp;following&nbsp;gemcitabine&nbsp;or&nbsp;day&nbsp;2&nbsp;of&nbsp;each&nbsp;28-day&nbsp;cycle.&nbsp;This&nbsp;4-week&nbsp;cycle is&nbsp;then&nbsp;repeated.&nbsp;Dosage&nbsp;reduction with&nbsp;each&nbsp;cycle or&nbsp;within&nbsp;a&nbsp;cycle may&nbsp;be&nbsp;applied based upon the grade of toxicity experienced by the patient.</p><p><u>Pancreatic&nbsp;cancer</u></p><p>The recommended dose of&nbsp;gemcitabine&nbsp;is&nbsp;1000&nbsp;mg/m2,&nbsp;given&nbsp;by&nbsp;30-minute intravenous&nbsp;infusion. This should&nbsp;be repeated&nbsp;once weekly&nbsp;for&nbsp;up&nbsp;to&nbsp;7&nbsp;weeks followed by&nbsp;a&nbsp;week&nbsp;of&nbsp;rest. Subsequent cycles&nbsp;should consist&nbsp;of&nbsp;injections once weekly for&nbsp;3&nbsp;consecutive&nbsp;weeks&nbsp;out&nbsp;of&nbsp;every 4&nbsp;weeks.&nbsp;Dosage&nbsp;reduction with each cycle or&nbsp;within a cycle may be applied based upon the grade of toxicity&nbsp;experienced by&nbsp;the&nbsp;patient.</p><p><u>Non&nbsp;small&nbsp;cell&nbsp;lung&nbsp;cancer</u></p><p><em>Monotherapy&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</em></p><p>The&nbsp;recommended&nbsp;dose&nbsp;of&nbsp;gemcitabine&nbsp;is&nbsp;1000&nbsp;mg/m&nbsp;,&nbsp;given&nbsp;by&nbsp;30-minute&nbsp;intravenous&nbsp;infusion.&nbsp;This&nbsp;should be repeated once weekly for 3&nbsp;weeks, followed by&nbsp;a 1-week rest period. This 4-week cycle is thenrepeated. Dosage reduction&nbsp;with&nbsp;each&nbsp;cycle or&nbsp;within&nbsp;a&nbsp;cycle may&nbsp;be&nbsp;applied&nbsp;based&nbsp;upon&nbsp;the&nbsp;grade of toxicity experienced by the patient.</p><p><em>Combination&nbsp;use</em></p><p>The recommended dose for gemcitabine&nbsp;is 1250 mg/m2&nbsp;body surface area given as a&nbsp;30-minute intravenousinfusion&nbsp;on&nbsp;Day&nbsp;1&nbsp;and&nbsp;8&nbsp;of&nbsp;the treatment&nbsp;cycle (21&nbsp;days).&nbsp;Dosage reduction with&nbsp;each cycle or&nbsp;within&nbsp;a&nbsp;cycle may&nbsp;be&nbsp;applied&nbsp;based&nbsp;upon&nbsp;the&nbsp;grade of&nbsp;toxicity&nbsp;experienced&nbsp;by&nbsp;the&nbsp;patient. Cisplatin has been used&nbsp;at doses between 75-100 mg/m2&nbsp;once every 3 weeks.</p><p><u>Breast&nbsp;cancer</u></p><p><em>Combination&nbsp;use</em></p><p>Gemcitabine&nbsp;in&nbsp;combination&nbsp;with&nbsp;paclitaxel&nbsp;is&nbsp;recommended&nbsp;using&nbsp;paclitaxel&nbsp;(175&nbsp;mg/m2)&nbsp;administered on&nbsp;Day&nbsp;1&nbsp;over&nbsp;approximately 3-hours as&nbsp;an&nbsp;intravenous&nbsp;infusion,&nbsp;followed&nbsp;by&nbsp;gemcitabine (1250 mg/m2) as&nbsp;a 30-minute&nbsp;intravenous&nbsp;infusion on Days 1&nbsp;and 8&nbsp;of each 21-day cycle.&nbsp;Dose reduction&nbsp;with&nbsp;eachcycle or&nbsp;within&nbsp;a&nbsp;cycle may&nbsp;be&nbsp;applied&nbsp;based&nbsp;upon&nbsp;the&nbsp;grade of&nbsp;toxicity&nbsp;experienced by&nbsp;the patient. Patients should have an&nbsp;absolute granulocyte&nbsp;count of at&nbsp;least 1,500 (x&nbsp;106/l)&nbsp;prior&nbsp;to&nbsp;initiation&nbsp;of&nbsp;gemcitabine&nbsp;+&nbsp;paclitaxel&nbsp;combination.</p><p><u>Ovarian&nbsp;cancer</u></p><p><em>Combination&nbsp;use</em></p><p>Gemcitabine&nbsp;in&nbsp;combination with&nbsp;carboplatin is recommended using&nbsp;gemcitabine 1000&nbsp;mg/m2&nbsp;administered on Days 1&nbsp;and 8&nbsp;of each 21-day cycle as&nbsp;a 30-minute&nbsp;intravenous&nbsp;infusion. After gemcitabine, carboplatin will&nbsp;be given&nbsp;on&nbsp;Day&nbsp;1&nbsp;consistent with&nbsp;a&nbsp;target&nbsp;Area under curve&nbsp;(AUC) of&nbsp;4.0&nbsp;mg/ml∙min.&nbsp;Dosage reduction&nbsp;with&nbsp;each&nbsp;cycle or&nbsp;within&nbsp;a&nbsp;cycle may&nbsp;be&nbsp;applied&nbsp;based&nbsp;upon&nbsp;the grade of toxicity experienced by the patient.</p><p>&nbsp;</p><p><u>Monitoring&nbsp;for&nbsp;toxicity&nbsp;and&nbsp;dose&nbsp;modification&nbsp;due&nbsp;to&nbsp;toxicity</u></p><p><em>Dose&nbsp;modification&nbsp;due&nbsp;to&nbsp;non&nbsp;haematological&nbsp;toxicity</em></p><p>Periodic physical&nbsp;examination and&nbsp;checks of renal&nbsp;and&nbsp;hepatic function should be made to&nbsp;detect non- haematological&nbsp;toxicity.&nbsp;Dosage&nbsp;reduction&nbsp;with&nbsp;each&nbsp;cycle&nbsp;or&nbsp;within&nbsp;a&nbsp;cycle&nbsp;may&nbsp;be&nbsp;applied&nbsp;based&nbsp;upon the grade of toxicity experienced by the patient. In general, for severe (Grade 3&nbsp;or 4) non- haematological&nbsp;toxicity,&nbsp;except nausea/vomiting, therapy with&nbsp;gemcitabine&nbsp;should&nbsp;be withheld&nbsp;or decreased depending on&nbsp;the judgement of the treating physician. Doses should be withheld until toxicity has resolved in the opinion of the physician.</p><p>For&nbsp;cisplatin,&nbsp;carboplatin,&nbsp;and&nbsp;paclitaxel&nbsp;dosage adjustment&nbsp;in&nbsp;combination therapy,&nbsp;please refer&nbsp;to&nbsp;the corresponding Summary of Product Characteristics.</p><p><em>Dose&nbsp;modification&nbsp;due&nbsp;to&nbsp;haematological&nbsp;toxicity Initiation of a cycle</em></p><p>For all&nbsp;indications, the patient must be monitored before each dose for platelet and granulocyte counts. Patients should&nbsp;have an&nbsp;absolute granulocyte&nbsp;count&nbsp;of&nbsp;at&nbsp;least&nbsp;1,500&nbsp;(x&nbsp;106/l)&nbsp;and&nbsp;platelet account of 100,000 (x 106/l) prior to the initiation of a cycle.</p><p><em>Within a&nbsp;cycle</em></p><p>Dose&nbsp;modifications&nbsp;of&nbsp;gemcitabine&nbsp;within&nbsp;a&nbsp;cycle&nbsp;should&nbsp;be&nbsp;performed&nbsp;according&nbsp;to&nbsp;the&nbsp;following&nbsp;tables:</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="3"><p><strong>Dose&nbsp;modification&nbsp;of&nbsp;gemcitabine&nbsp;within&nbsp;a&nbsp;cycle&nbsp;for&nbsp;bladder&nbsp;cancer, NSCLC&nbsp;and&nbsp;pancreatic</strong></p><p><strong>cancer,&nbsp;given&nbsp;in&nbsp;monotherapy&nbsp;or&nbsp;in&nbsp;combination&nbsp;with&nbsp;cisplatin</strong></p></td></tr><tr><td><p><strong>Absolute&nbsp;granulocyte&nbsp;count</strong></p><p><strong>(x&nbsp;106/l)</strong></p></td><td><p><strong>Plate&nbsp;let&nbsp;count</strong></p><p><strong>(x&nbsp;106/l)</strong></p></td><td><p><strong>Percentage of standard dose&nbsp;of&nbsp;gemcitabine&nbsp;(%)</strong></p></td></tr><tr><td><p>&gt;&nbsp;1,000&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and</p></td><td><p>&gt;&nbsp;100,000</p></td><td><p>100</p></td></tr><tr><td><p>500-1,000&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;or</p></td><td><p>50,000-100,000</p></td><td><p>75</p></td></tr><tr><td><p>&lt;500&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;or</p></td><td><p>&lt;&nbsp;50,000</p></td><td><p>Omit&nbsp;dose&nbsp;*</p></td></tr></tbody></table><p>*Treatment&nbsp;omitted&nbsp;will&nbsp;not&nbsp;be&nbsp;re-instated&nbsp;within&nbsp;a&nbsp;cycle&nbsp;before the&nbsp;absolute granulocyte&nbsp;count reaches at least&nbsp;500 (x106/l) and the platelet count reaches 50,000 (x106/l).</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="4"><p><strong>Dose&nbsp;modification&nbsp;of&nbsp;gemcitabine&nbsp;within&nbsp;a&nbsp;cycle&nbsp;for&nbsp;breast&nbsp;cancer,&nbsp;given&nbsp;in&nbsp;combination&nbsp;with&nbsp;paclitaxel</strong></p></td></tr><tr><td colspan="2"><p><strong>Absolute&nbsp;granulocyte&nbsp;count</strong></p><p>(x&nbsp;106/l)</p></td><td><p><strong>Plate&nbsp;let&nbsp;count</strong></p><p><strong>(x&nbsp;106/l)</strong></p></td><td><p><strong>Pe&nbsp;rcentage&nbsp;of&nbsp;standard</strong></p><p><strong>dose&nbsp;of&nbsp;gemcitabine&nbsp;(%)</strong></p></td></tr><tr><td><p>&ge;&nbsp;1,200</p></td><td><p>and</p></td><td><p>&gt;75,000</p></td><td><p>100</p></td></tr><tr><td><p>1,000-&nbsp;&lt;1,200</p></td><td><p>or</p></td><td><p>50,000-75,000</p></td><td><p>75</p></td></tr><tr><td><p>700-&nbsp;&lt;1,000</p></td><td><p>and</p></td><td><p>&ge;&nbsp;50,000</p></td><td><p>50</p></td></tr><tr><td><p>&lt;700</p></td><td><p>or</p></td><td><p>&lt;50,000</p></td><td><p>Omit&nbsp;dose*</p></td></tr></tbody></table><p>*Treatment&nbsp;omitted&nbsp;will&nbsp;not&nbsp;be&nbsp;re-instated within&nbsp;a&nbsp;cycle.&nbsp;Treatment&nbsp;will&nbsp;start&nbsp;on&nbsp;day&nbsp;1&nbsp;of&nbsp;the&nbsp;next&nbsp;cycle&nbsp;once the&nbsp;absolute granulocyte&nbsp;count&nbsp;reaches at&nbsp;least&nbsp;1,500&nbsp;(x106/l) and&nbsp;the&nbsp;platelet&nbsp;count&nbsp;reaches 100,000 (x106/l).</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="3"><p><strong>Dose&nbsp;modification&nbsp;of&nbsp;gemcitabine&nbsp;within&nbsp;a&nbsp;cycle&nbsp;for&nbsp;ovarian&nbsp;cancer,&nbsp;given&nbsp;in&nbsp;combination with&nbsp;carboplatin</strong></p></td></tr><tr><td><p><strong>Absolute&nbsp;granulocyte&nbsp;count</strong></p><p><strong>(x&nbsp;106/l)</strong></p></td><td><p><strong>Plate&nbsp;let&nbsp;count</strong></p><p><strong>(x&nbsp;106/l)</strong></p></td><td><p><strong>Perce&nbsp;ntage&nbsp;of&nbsp;standard</strong></p><p><strong>dose&nbsp;of&nbsp;gemcitabine&nbsp;(%)</strong></p></td></tr></tbody></table><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>&gt;&nbsp;1,500&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and</p></td><td><p>&ge;&nbsp;100,000</p></td><td><p>100</p></td></tr><tr><td><p>1000-1,500&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;or</p></td><td><p>75,000-100,000</p></td><td><p>50</p></td></tr><tr><td><p>&lt;1000&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;or</p></td><td><p>&lt;&nbsp;75,000</p></td><td><p>Omit&nbsp;dose*</p></td></tr></tbody></table><p>*Treatment&nbsp;omitted&nbsp;will&nbsp;not&nbsp;be&nbsp;re-instated within&nbsp;a&nbsp;cycle.&nbsp;Treatment&nbsp;will&nbsp;start&nbsp;on&nbsp;day&nbsp;1&nbsp;of&nbsp;the&nbsp;next</p><p>&nbsp;</p><p>cycle&nbsp;once the&nbsp;absolute granulocyte&nbsp;count&nbsp;reaches at&nbsp;least&nbsp;1,500&nbsp;(x106/l) and&nbsp;the&nbsp;platelet count&nbsp;reaches 100,000 (x106/l).</p><p><em>Dose&nbsp;modifications&nbsp;due&nbsp;to&nbsp;haematological&nbsp;toxicity&nbsp;in&nbsp;subsequent&nbsp;cycles,&nbsp;for&nbsp;all&nbsp;indications</em></p><p>The&nbsp;gemcitabine&nbsp;dose&nbsp;should&nbsp;be&nbsp;reduced&nbsp;to&nbsp;75%&nbsp;of&nbsp;the&nbsp;original&nbsp;cycle initiation&nbsp;dose,&nbsp;in&nbsp;the&nbsp;case&nbsp;of&nbsp;the</p><p>following haematological&nbsp;toxicities:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->Absolute&nbsp;granulocyte&nbsp;count&nbsp;&lt;&nbsp;500&nbsp;x&nbsp;10&nbsp;/l&nbsp;for&nbsp;more&nbsp;than&nbsp;5&nbsp;days</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->Absolute&nbsp;granulocyte&nbsp;count&nbsp;&lt;&nbsp;100&nbsp;x&nbsp;106/l&nbsp;for&nbsp;more&nbsp;than&nbsp;3&nbsp;days</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->Febrile&nbsp;neutropaenia&nbsp;&nbsp;&nbsp;&nbsp;6</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->Platelets&nbsp;&lt;&nbsp;25,000&nbsp;x&nbsp;10&nbsp;/l</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->Cycle&nbsp;delay&nbsp;of&nbsp;more&nbsp;than&nbsp;1&nbsp;week&nbsp;due&nbsp;to&nbsp;toxicity&nbsp;<u>Method of administration</u></p><p>The&nbsp;medicinal&nbsp;product&nbsp;is&nbsp;tolerated&nbsp;well&nbsp;during&nbsp;infusion&nbsp;and&nbsp;may&nbsp;be&nbsp;administered&nbsp;ambulant.&nbsp;If&nbsp;extravasation&nbsp;occurs,&nbsp;generally&nbsp;the&nbsp;infusion&nbsp;must&nbsp;be&nbsp;stopped&nbsp;immediately and&nbsp;started&nbsp;again&nbsp;in&nbsp;another blood vessel. The patient should be monitored carefully after the&nbsp;administration.</p><p>For&nbsp;instructions&nbsp;on&nbsp;reconstitution&nbsp;of&nbsp;the&nbsp;medicinal&nbsp;product&nbsp;before&nbsp;administration,&nbsp;see&nbsp;section&nbsp;6.6</p><p><u>Special&nbsp;populations</u></p><p><em>Patients&nbsp;with&nbsp;renal&nbsp;or&nbsp;hepatic&nbsp;impairment</em></p><p>Gemcitabine&nbsp;should&nbsp;be&nbsp;used&nbsp;with&nbsp;caution in&nbsp;patients with&nbsp;hepatic or&nbsp;renal&nbsp;impairment&nbsp;as&nbsp;there&nbsp;is insufficient information from&nbsp;clinical&nbsp;studies to&nbsp;allow for&nbsp;clear&nbsp;dose recommendations&nbsp;for&nbsp;these patient populations (see sections 4.4 and 5.2).</p><p><em>Older&nbsp;people(&gt;&nbsp;65&nbsp;years)</em></p><p>Gemcitabine&nbsp;has&nbsp;been&nbsp;well&nbsp;tolerated&nbsp;in&nbsp;patients over&nbsp;the age of&nbsp;65.&nbsp;There is&nbsp;no&nbsp;evidence to&nbsp;suggest that dose adjustments, other than&nbsp;those already recommended for all&nbsp;patients, are necessary in&nbsp;the older people (see section 5.2).</p><p><em>Paediatric&nbsp;population&nbsp;(&lt;&nbsp;18&nbsp;years)</em></p><p>Gemcitabine&nbsp;is&nbsp;not&nbsp;recommended for&nbsp;use&nbsp;in&nbsp;children&nbsp;under&nbsp;18&nbsp;years&nbsp;of&nbsp;age&nbsp;due&nbsp;to&nbsp;insufficient&nbsp;data&nbsp;on safety and efficacy.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1 Breast-feeding (see section 4.6).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Prolongation of&nbsp;the&nbsp;infusion&nbsp;time&nbsp;and&nbsp;increased&nbsp;dosing&nbsp;frequency&nbsp;have&nbsp;been&nbsp;shown&nbsp;to&nbsp;increase&nbsp;toxicity.</p><p>&nbsp;</p><p><em>Haematological&nbsp;toxicity</em></p><p>Gemcitabine&nbsp;can&nbsp;suppress bone marrow&nbsp;function&nbsp;as&nbsp;manifested&nbsp;by&nbsp;leucopaenia, thrombocytopaenia and anaemia. Patients receiving gemcitabine&nbsp;should be monitored prior to&nbsp;each dose&nbsp;for platelet, leucocyte&nbsp;andgranulocyte counts.&nbsp;Suspension&nbsp;or&nbsp;modification&nbsp;of&nbsp;therapy&nbsp;should&nbsp;be&nbsp;considered&nbsp;when drug-induced&nbsp;bone marrow depression&nbsp;is&nbsp;detected&nbsp;(see section 4.2). However,&nbsp;myelosuppression&nbsp;is short lived and usually does not result in&nbsp;dose reduction and rarely in&nbsp;discontinuation.&nbsp;Peripheral blood counts may continue to&nbsp;deteriorate&nbsp;after&nbsp;gemcitabine&nbsp;administration has been stopped. In patients with impaired bone marrow function, the treatment should be started with&nbsp;caution. As with other&nbsp;cytotoxic treatments,&nbsp;the&nbsp;risk&nbsp;of&nbsp;cumulative&nbsp;bone-marrow suppression&nbsp;must&nbsp;be&nbsp;considered&nbsp;when gemcitabine&nbsp;treatment is given together with other chemotherapy.</p><p>&nbsp;</p><p><em>Hepatic&nbsp;and&nbsp;renal&nbsp;impairment</em></p><p>Administration of gemcitabine in patients with&nbsp;concurrent liver metastases or a pre-existing medical history of hepatitis, alcoholism or liver cirrhosis may lead to&nbsp;exacerbation of the underlying hepatic&nbsp;insufficiency.</p><p>Laboratory&nbsp;evaluation&nbsp;of&nbsp;renal&nbsp;and&nbsp;hepatic&nbsp;function&nbsp;(including&nbsp;virological&nbsp;tests)&nbsp;should&nbsp;be&nbsp;performed&nbsp;periodically.</p><p>Gemcitabine should be used&nbsp;with&nbsp;caution in patients with hepatic or renal&nbsp;function impairment as there is insufficient information from clinical studies to&nbsp;allow clear dose recommendation for this patient population (see section 4.2).</p><p>&nbsp;</p><p><em>Concomitant&nbsp;radiotherapy</em></p><p>Concomitant&nbsp;radiotherapy&nbsp;(given&nbsp;together&nbsp;or&nbsp;7&nbsp;days&nbsp;apart):&nbsp;Toxicity&nbsp;has&nbsp;been&nbsp;reported&nbsp;(see&nbsp;section</p><p><!--[if !supportLists]-->4.3&nbsp;<!--[endif]-->for&nbsp;details&nbsp;and&nbsp;recommendations&nbsp;for&nbsp;use).</p><p>&nbsp;</p><p><em>Live&nbsp;vaccinations</em></p><p>Yellow fever&nbsp;vaccine and&nbsp;other&nbsp;live&nbsp;attenuated&nbsp;vaccines are&nbsp;not&nbsp;recommended in&nbsp;patients treated&nbsp;with gemcitabine&nbsp;(see section 4.5).</p><p>&nbsp;</p><p><em>Posterior&nbsp;reversible&nbsp;encephalopathy&nbsp;syndrome</em></p><p>Reports&nbsp;of&nbsp;posterior&nbsp;reversible&nbsp;encephalopathy syndrome (PRES)&nbsp;with&nbsp;potentially&nbsp;severe&nbsp;consequences have been reported in&nbsp;patients receiving gemcitabine as single agent or in&nbsp;combination with&nbsp;other chemotherapeutic&nbsp;agents. Acute&nbsp;hypertension and&nbsp;seizure activity were reported in&nbsp;most gemcitabine patients experiencing PRES, but other symptoms such as headache, lethargy, confusion and&nbsp;blindness could also&nbsp;be present. Diagnosis is optimally confirmed by&nbsp;magnetic resonance imaging (MRI).&nbsp;PRES was&nbsp;typically reversible with&nbsp;appropriatesupportive measures. Gemcitabine&nbsp;should be permanently discontinued and supportive&nbsp;measures implemented, including blood pressure control&nbsp;and&nbsp;anti-seizure&nbsp;therapy,&nbsp;if&nbsp;PRES&nbsp;develops&nbsp;during&nbsp;therapy.</p><p>&nbsp;</p><p><em>Cardiovascular</em></p><p>Due&nbsp;to&nbsp;the&nbsp;risk&nbsp;of&nbsp;cardiac and/or&nbsp;vascular disorders with&nbsp;gemcitabine,&nbsp;particular caution must&nbsp;be exercised with patients presenting a history of cardiovascular&nbsp;events.</p><p>&nbsp;</p><p><em>Capillary leak&nbsp;syndrome</em></p><p>Capillary leak&nbsp;syndrome&nbsp;has been&nbsp;reported in&nbsp;patients receiving gemcitabine as single agent or in combination with&nbsp;other&nbsp;chemotherapeutic&nbsp;agents (see section&nbsp;4.8).&nbsp;The condition&nbsp;is&nbsp;usually&nbsp;treatable if recognised&nbsp;early&nbsp;andmanaged&nbsp;appropriately,&nbsp;but&nbsp;fatal&nbsp;cases&nbsp;have&nbsp;been&nbsp;reported. The&nbsp;condition&nbsp;involves systemic capillaryhyperpermeability&nbsp;during&nbsp;which&nbsp;fluid&nbsp;and&nbsp;proteins&nbsp;from&nbsp;the&nbsp;intravascular space&nbsp;leak into&nbsp;the&nbsp;interstiium.&nbsp;Theclinical&nbsp;features include generalised&nbsp;oedema,&nbsp;weight&nbsp;gain,&nbsp;hypoalbuminaemia, severe hypotension, acute renalimpairment and&nbsp;pulmonary oedema. Gemcitabine&nbsp;should bediscontinued&nbsp;and&nbsp;supportive&nbsp;measures implemented&nbsp;if capillary leak&nbsp;syndrome develops during therapy. Capillary&nbsp;leak&nbsp;syndrome&nbsp;can&nbsp;occur&nbsp;in&nbsp;later&nbsp;cycles&nbsp;and&nbsp;has&nbsp;been&nbsp;associated&nbsp;in&nbsp;the&nbsp;literature with adult respiratory distress syndrome.</p><p>&nbsp;</p><p><em>Pulmonary</em></p><p>Pulmonary effects, sometimes&nbsp;severe&nbsp;(such&nbsp;as&nbsp;pulmonary oedema, interstitial&nbsp;pneumonitis&nbsp;or adult respiratory distress syndrome (ARDS)) have&nbsp;been&nbsp;reported&nbsp;in&nbsp;association with&nbsp;gemcitabine therapy. If such&nbsp;effects&nbsp;develop,consideration&nbsp;should&nbsp;be&nbsp;made&nbsp;to&nbsp;discontinuing gemcitabine&nbsp;therapy. Early use&nbsp;of supportive&nbsp;care measure may help ameliorate the condition.</p><p>&nbsp;</p><p><em>Renal</em></p><p><em>Haemolytic&nbsp;uraemic&nbsp;syndrome</em></p><p>Clinical&nbsp;findings&nbsp;consistent&nbsp;with&nbsp;the&nbsp;haemolytic&nbsp;uraemic syndrome (HUS)&nbsp;were&nbsp;rarely&nbsp;reported&nbsp;(post- marketing data) in&nbsp;patients receiving gemcitabine (see&nbsp;section 4.8). HUS is a potentially life- threatening disorder. Gemcitabine&nbsp;should be discontinued at&nbsp;the first signs of any&nbsp;evidence of microangiopathic&nbsp;haemolytic&nbsp;anaemia, such&nbsp;as rapidly falling&nbsp;haemoglobin with&nbsp;concomitant thrombocytopaenia,&nbsp;elevation of serum bilirubin, serum creatinine, blood urea nitrogen, or LDH. Renal&nbsp;failure may&nbsp;not be reversible with&nbsp;discontinuation of therapy anddialysis may&nbsp;be required.</p><p>&nbsp;</p><p><em>Fertility</em></p><p>In&nbsp;fertility&nbsp;studies&nbsp;gemcitabine&nbsp;caused&nbsp;hypospermatogenesis&nbsp;in&nbsp;male&nbsp;mice&nbsp;(see&nbsp;section&nbsp;5.3).&nbsp;Therefore, men being treated&nbsp;with gemcitabine&nbsp;are&nbsp;advised not to&nbsp;father a&nbsp;child during and up&nbsp;to&nbsp;6&nbsp;months after treatment and toseek further&nbsp;advice&nbsp;regarding cryoconservation&nbsp;of sperm prior to&nbsp;treatment&nbsp;because of the possibility of infertility due to&nbsp;therapy with gemcitabine (see&nbsp;section 4.6).</p><p>&nbsp;</p><p><em>Sodium</em></p><p>Vial&nbsp;of&nbsp;200&nbsp;mg&nbsp;gemcitabine contains 3.56&nbsp;mg&nbsp;(&lt;1&nbsp;mmol)&nbsp;sodium. Vial&nbsp;of 1 g gemcitabine contains 17.81 mg (&lt; 1 mmol) sodium.<br />Vial&nbsp;of&nbsp;2&nbsp;g&nbsp;gemcitabine&nbsp;contains&nbsp;35.62&nbsp;mg&nbsp;(1.54&nbsp;mmol)&nbsp;sodium.<br />This&nbsp;should&nbsp;be&nbsp;taken&nbsp;into&nbsp;consideration&nbsp;by&nbsp;patients&nbsp;on&nbsp;a&nbsp;controlled&nbsp;sodium&nbsp;diet.</p><p>​​​​​​​</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No&nbsp;specific&nbsp;interaction&nbsp;studies&nbsp;have&nbsp;been&nbsp;performed&nbsp;(see&nbsp;section&nbsp;5.2)</p><p>&nbsp;</p><p><em>Radiotherapy</em></p><p>Concurrent (given together or 7 days apart) - Toxicity associated with this multimoda lity therapy is dependent on many different factors, including dose of gemcitabine, frequency of gemcitabine administration, dose of radiation, radiotherapy planning technique, the target tissue, and target&nbsp;volume. Pre-clinical&nbsp;and clinical&nbsp;studieshave&nbsp;shown that gemcitabine&nbsp;has&nbsp;radio sensitising activity. In a single trial, where gemcitabine at a dose of 1,000 mg/m2 was administered concurrently for up to 6 consecutive weeks with therapeutic thoracic radiation to patients with non-small cell lung cancer, significant toxicity in the form of severe, and potentially life threatening mucositis, especially oesophagitis, and pneumonitis was observed, particularly in patients receiving large volumes of radiotherapy&nbsp;[median&nbsp;treatment&nbsp;volumes&nbsp;4,795&nbsp;cm3].&nbsp;Studies&nbsp;done&nbsp;subsequently&nbsp;havesuggested&nbsp;that&nbsp;it is feasible to administer gemcitabine at lower doses with concurrent radiotherapy with predictable toxicity, such as a phase II study in non-small cell lung cancer, where thoracic radiation doses of&nbsp;66&nbsp;Gy&nbsp;were&nbsp;applied&nbsp;concomitantly&nbsp;with&nbsp;an&nbsp;administration&nbsp;with&nbsp;gemcitabine&nbsp;(600&nbsp;mg/m2,&nbsp;four&nbsp;times) and cisplatin (80 mg/m2 twice) during 6 weeks. The optimum regimen for safe administration of gemcitabine with therapeutic doses of radiation has not yet been determined in all tumour types.</p><p>Non-concurrent (given &gt;7 days apart)- Analysis of the data does not indicate any enhanced toxicity when gemcitabine is administered more than 7 days before or after radiation, other than radiation recall.&nbsp;Data&nbsp;suggestthat&nbsp;gemcitabine&nbsp;can&nbsp;be&nbsp;started&nbsp;after&nbsp;the&nbsp;acute&nbsp;effects&nbsp;of&nbsp;radiation&nbsp;have&nbsp;resolved or at least one week after radiation.</p><p>Radiation&nbsp;injury&nbsp;has&nbsp;been&nbsp;reported&nbsp;on&nbsp;targeted&nbsp;tissues&nbsp;(e.g.&nbsp;oesophagitis,&nbsp;colitis,&nbsp;and&nbsp;pneumonitis)&nbsp;in association with both concurrent and non-concurrent use of gemcitabine.</p><p>&nbsp;</p><p><em>Others</em><br />Yellow fever&nbsp;and&nbsp;other&nbsp;live&nbsp;attenuated&nbsp;vaccines are&nbsp;not&nbsp;recommended due&nbsp;to&nbsp;the&nbsp;risk&nbsp;of&nbsp;systemic, possibly fatal, disease, particularly&nbsp;in immunosuppressed&nbsp;patients.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>There&nbsp;are&nbsp;no&nbsp;adequate data from&nbsp;the use of&nbsp;gemcitabine&nbsp;in&nbsp;pregnant women. Studies in&nbsp;anima ls haveshown reproductive&nbsp;toxicity (see&nbsp;section 5.3). Based on&nbsp;results from&nbsp;animal&nbsp;studies and the&nbsp;mechanism of action of gemcitabine, this substance should not be used during pregnancy&nbsp;unless&nbsp;clearly&nbsp;necessary. Women&nbsp;should&nbsp;be&nbsp;advised&nbsp;not&nbsp;to&nbsp;become pregnant&nbsp;during treatment with&nbsp;gemcitabine&nbsp;and&nbsp;to&nbsp;warn&nbsp;their attending physician&nbsp;immediately, should this occur after all.</p><p><u>Breast-feeding</u></p><p>It&nbsp;is not known whether gemcitabine&nbsp;is excreted in&nbsp;human milk&nbsp;and&nbsp;adverse effects on&nbsp;the&nbsp;suckling&nbsp;child cannot be excluded.&nbsp;Breast-feeding must be discontinued during&nbsp;gemcitabine therapy.</p><p><u>Fertility</u></p><p>In&nbsp;fertility studies gemcitabine&nbsp;caused hypospermatogenesis&nbsp;in&nbsp;male mice (see&nbsp;section 5.3). Therefore,men&nbsp;being treated&nbsp;with&nbsp;gemcitabine&nbsp;are&nbsp;advised not to&nbsp;father a&nbsp;child&nbsp;during&nbsp;and&nbsp;up&nbsp;to 6&nbsp;months aftertreatment and&nbsp;to&nbsp;seek&nbsp;further&nbsp;advice regarding&nbsp;cryoconservation&nbsp;of&nbsp;sperm prior&nbsp;to treatment because&nbsp;of&nbsp;the&nbsp;possibility&nbsp;of&nbsp;infertility&nbsp;due&nbsp;to&nbsp;therapy&nbsp;with&nbsp;gemcitabine.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No&nbsp;studies on&nbsp;the effects on&nbsp;the&nbsp;ability to&nbsp;drive and&nbsp;use machines have been performed. However,gemcitabine&nbsp;has&nbsp;been&nbsp;reported&nbsp;to&nbsp;cause mild&nbsp;to&nbsp;moderate&nbsp;somnolence,&nbsp;especially&nbsp;in combination withalcohol&nbsp;consumption.&nbsp;Patients should be cautioned against driving or operating machinery until it isestablished that they do&nbsp;not become somnolent.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The most commonly reported adverse drug reactions associated with Gemcitabine treatment include: nausea with or without vomiting, raised liver transaminases (AST/ALT) and alkaline phosphatase, reported in approximately 60% of patients; proteinuria and haematuria reported in approximately 50% patients; dyspnoea reported in 10-40% of patients (highest incidence in lung cancer patients); allergic skin rashes occur in approximately 25% of patients and are associated with itching in 10% of patients. The&nbsp;frequency&nbsp;and&nbsp;severity&nbsp;of&nbsp;the&nbsp;adverse&nbsp;reactionsare&nbsp;affected&nbsp;by&nbsp;the&nbsp;dose,&nbsp;infusion&nbsp;rate&nbsp;and&nbsp;intervals between doses (see section 4.4). Dose-limiting adverse reactions are reductions in thrombocyte, leucocyte and granulocyte counts (see section 4.2).</p><p><u>Clinical&nbsp;trial&nbsp;data</u></p><p>Frequencies&nbsp;are&nbsp;defined&nbsp;as:&nbsp;Very&nbsp;common&nbsp;(&ge;1/10),&nbsp;Common&nbsp;(&ge;1/100&nbsp;to&nbsp;&lt;1/10),&nbsp;Uncommon&nbsp;(&ge;1/1000&nbsp;to&nbsp;&lt;1/100),&nbsp;Rare&nbsp;(&ge;1/10,000&nbsp;to&nbsp;&lt;1/1000),&nbsp;Very&nbsp;Rare&nbsp;(&lt;1/10,000).</p><p>The&nbsp;following&nbsp;table&nbsp;of&nbsp;undesirable&nbsp;effects&nbsp;and&nbsp;frequencies&nbsp;is&nbsp;based&nbsp;on&nbsp;data&nbsp;from&nbsp;clinical&nbsp;trials.&nbsp;Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>System&nbsp;Organ&nbsp;Class</p></td><td><p>Frequency&nbsp;grouping</p></td></tr><tr><td><p>Blood&nbsp;and&nbsp;lymphatic&nbsp;system&nbsp;disorders</p></td><td><p>Very&nbsp;common</p><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;<!--[endif]-->Leucopaenia&nbsp;(Neutropaenia&nbsp;Grade&nbsp;3&nbsp;=&nbsp;19.3&nbsp;%;&nbsp;Grade&nbsp;4&nbsp;=&nbsp;6&nbsp;%).</p><p>Bone-marrow&nbsp;suppression&nbsp;is&nbsp;usually&nbsp;mild&nbsp;to&nbsp;moderate&nbsp;and&nbsp;mostly&nbsp;affects&nbsp;the granulocyte count (see section 4.2 and 4.4)</p><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;<!--[endif]-->Thrombocytopaenia</p><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;<!--[endif]-->Anaemia Common</p><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;<!--[endif]-->Febrileneutropaenia Very rare</p><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;<!--[endif]-->Thrombocytosis</p></td></tr><tr><td><p>Immune&nbsp;system&nbsp;disorders</p></td><td><p>Very&nbsp;Rare</p><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;<!--[endif]-->Anaphylactoid&nbsp;reaction</p></td></tr><tr><td><p>Metabolism&nbsp;and&nbsp;nutritiondisorders</p></td><td><p>Common</p><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;<!--[endif]-->Anorexia</p></td></tr></tbody></table><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>Nervous&nbsp;system&nbsp;disorders</p></td><td><p>Common</p><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;<!--[endif]-->Headache</p><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;<!--[endif]-->Insomnia</p><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;<!--[endif]-->Somnolence&nbsp;Very rare</p><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;<!--[endif]-->Posterior&nbsp;reversible&nbsp;encephalopathy&nbsp;syndrome&nbsp;(see&nbsp;section&nbsp;4.4)</p></td></tr><tr><td><p>Cardiac&nbsp;disorders</p></td><td><p>Rare</p><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;<!--[endif]-->Myocardial&nbsp;infarct</p></td></tr><tr><td><p>Vascular&nbsp;disorders</p></td><td><p>Rare</p><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;<!--[endif]-->Hypotension&nbsp;Very rare</p><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;<!--[endif]-->Capillary&nbsp;leak&nbsp;syndrome&nbsp;(see&nbsp;section&nbsp;4.4)</p></td></tr><tr><td><p>Respiratory,&nbsp;thoracic&nbsp;and mediastinal disorders</p></td><td><p>Very&nbsp;common</p><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;<!--[endif]-->Dyspnoea&nbsp;&ndash;usually&nbsp;mild&nbsp;and&nbsp;passes&nbsp;rapidly&nbsp;withouttreatment&nbsp;Common</p><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;<!--[endif]-->Cough</p><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;<!--[endif]-->Rhinitis Uncommon</p><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;<!--[endif]-->Interstitial&nbsp;pneumonitis&nbsp;(see&nbsp;section&nbsp;4.4)</p><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;<!--[endif]-->Bronchospasm&nbsp;&ndash;usually&nbsp;mild&nbsp;and&nbsp;transient&nbsp;but&nbsp;may&nbsp;require&nbsp;parenteral&nbsp;treatment</p></td></tr><tr><td><p>Gastrointestinal&nbsp;disorders</p></td><td><p>Very&nbsp;common</p><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;<!--[endif]-->Vomiting</p><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;<!--[endif]-->Nausea Common</p><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;<!--[endif]-->Diarrhoea</p><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;<!--[endif]-->Stomatitis&nbsp;and&nbsp;ulceration&nbsp;of&nbsp;the&nbsp;mouth</p><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;<!--[endif]-->Constipation</p></td></tr><tr><td><p>Hepatobiliary&nbsp;disorders</p></td><td><p>Very&nbsp;common</p><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;<!--[endif]-->Elevation&nbsp;of&nbsp;liver&nbsp;transaminases&nbsp;(AST&nbsp;and&nbsp;ALT)&nbsp;and&nbsp;alkalinephosphatase&nbsp;Common</p><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;<!--[endif]-->Increasedbilirubin&nbsp;Rare</p><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;<!--[endif]-->Increased&nbsp;gamma-glutamyl&nbsp;transferase&nbsp;(GGT)</p></td></tr><tr><td><p>Skin&nbsp;and&nbsp;subcutaneous&nbsp;tissue&nbsp;disorders</p></td><td><p>Very&nbsp;common</p><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;<!--[endif]-->Allergic&nbsp;skin&nbsp;rash&nbsp;frequently&nbsp;associated&nbsp;with&nbsp;pruritus</p><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;<!--[endif]-->Alopecia Common</p><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;<!--[endif]-->Itching</p><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;<!--[endif]-->Sweating&nbsp;Rare</p><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;<!--[endif]-->Ulceration</p><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;<!--[endif]-->Vesicle&nbsp;and&nbsp;sore&nbsp;formation</p><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;<!--[endif]-->Scaling&nbsp;Very&nbsp;rare</p><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;<!--[endif]-->Severe&nbsp;skin&nbsp;reactions,&nbsp;including&nbsp;desquamation&nbsp;and&nbsp;bullous&nbsp;skin&nbsp;eruptions</p></td></tr><tr><td><p>Musculoskeletal&nbsp;and&nbsp;connective tissue disorders</p></td><td><p>Common</p><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;<!--[endif]-->Back&nbsp;pain</p><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;<!--[endif]-->Myalgia</p></td></tr><tr><td><p>Renal&nbsp;and&nbsp;urinary&nbsp;disorders</p></td><td><p>Very&nbsp;Common</p><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;<!--[endif]-->Haematuria</p><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;<!--[endif]-->Mild&nbsp;proteinuria</p></td></tr><tr><td><p>General disorders and administration&nbsp;site&nbsp;conditions</p></td><td><p>Very&nbsp;common</p><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;<!--[endif]-->Influenza-like symptoms - the most common symptoms are fever, headache, chills,&nbsp;myalgia,&nbsp;asthenia&nbsp;and&nbsp;anorexia.&nbsp;Cough,&nbsp;rhinitis,&nbsp;malaise,&nbsp;perspirationand sleeping difficulties have also been reported.</p></td></tr></tbody></table><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>&nbsp;</p></td><td><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;<!--[endif]-->Oedema/peripheral&nbsp;oedema&nbsp;including&nbsp;facial&nbsp;oedema.&nbsp;Oedema&nbsp;isusually reversible after stopping treatment</p><p>Common</p><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;<!--[endif]-->Fever</p><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;<!--[endif]-->Asthenia</p><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;<!--[endif]-->Chills&nbsp;Rare</p><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;<!--[endif]-->Injection&nbsp;site&nbsp;reactions-mainly&nbsp;mild&nbsp;in&nbsp;nature</p></td></tr><tr><td><p>Injury,&nbsp;poisoning,&nbsp;and&nbsp;procedural&nbsp;Complications</p></td><td><p>Radiation&nbsp;toxicity&nbsp;(see&nbsp;section&nbsp;4.5).</p></td></tr></tbody></table><p>&nbsp;</p><p><u>Postmarketing&nbsp;experience&nbsp;(spontaneous&nbsp;reports)&nbsp;frequency&nbsp;not&nbsp;known&nbsp;(can&#39;t&nbsp;be&nbsp;estimated&nbsp;from&nbsp;the</u>&nbsp;<u>available data<em>)</em></u></p><p><em><u>Nervous&nbsp;system&nbsp;disorders</u></em>Cerebrovascular&nbsp;accident&nbsp;<em><u>Cardiac disorders</u></em></p><p>Arrythmias,&nbsp;predominantly&nbsp;supraventricular&nbsp;in&nbsp;nature Heart failure</p><p><em><u>Vascular&nbsp;disorders</u></em></p><p>Clinical&nbsp;signs&nbsp;of&nbsp;peripheral&nbsp;vasculitis&nbsp;and&nbsp;gangrene&nbsp;<em><u>Respiratory, thoracic and mediastinal disorders</u>&nbsp;</em>Pulmonary oedema</p><p>Adult&nbsp;respiratory&nbsp;distress&nbsp;syndrome&nbsp;(see&nbsp;section&nbsp;4.4)</p><p><em><u>Gastrointestinal&nbsp;disorders</u>&nbsp;</em>Ischaemic colitis&nbsp;<em><u>Hepatobiliary disorders</u></em></p><p>Serious&nbsp;hepatotoxicity,&nbsp;including&nbsp;liver&nbsp;failure&nbsp;and&nbsp;death</p><p><em><u>Skin&nbsp;and&nbsp;subcutaneous&nbsp;tissue&nbsp;disorders</u></em></p><p>Severe&nbsp;skin&nbsp;reactions,&nbsp;including&nbsp;desquamation&nbsp;and&nbsp;bullous&nbsp;skin&nbsp;eruptions,&nbsp;Lyell&#39;s&nbsp;Syndrome,&nbsp;Steven- Johnson Syndrome</p><p><em><u>Renal&nbsp;and&nbsp;urinary&nbsp;disorders</u></em></p><p>Renal&nbsp;failure&nbsp;(see&nbsp;section&nbsp;4.4)</p><p>Haemolytic&nbsp;uraemic&nbsp;syndrome&nbsp;(see&nbsp;section&nbsp;4.4)&nbsp;<em><u>Injury,poisoning&nbsp;and&nbsp;procedural&nbsp;complications</u>&nbsp;</em>Radiation recall</p><p><em><u>Combination&nbsp;use&nbsp;in&nbsp;breast&nbsp;cancer</u></em></p><p>The frequency of grade 3 and 4 haematological toxicities, particularly neutropaenia, increases when gemcitabineis&nbsp;used&nbsp;in&nbsp;combination&nbsp;with&nbsp;paclitaxel.&nbsp;However,&nbsp;the&nbsp;increase&nbsp;in&nbsp;these&nbsp;adverse&nbsp;reactions&nbsp;is not associated with an increased incidence of infections or haemorrhagic events. Fatigue and febrile neutropaenia&nbsp;occur&nbsp;more&nbsp;frequentlywhen&nbsp;gemcitabine&nbsp;is&nbsp;used&nbsp;in&nbsp;combination&nbsp;with&nbsp;paclitaxel.&nbsp;Fatigue, which is not associated with anaemia, usually resolves after the first cycle.</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="5"><p>Grade 3 and 4 Adverse Events Paclitaxel&nbsp;versus&nbsp;gemcitabine&nbsp;plus&nbsp;paclitaxel</p></td></tr><tr><td rowspan="3"><p>&nbsp;</p></td><td colspan="4"><p>Number&nbsp;(%)&nbsp;of&nbsp;Patients</p></td></tr><tr><td colspan="2"><p>Paclitaxel&nbsp;arm&nbsp;(N=259)</p></td><td colspan="2"><p>Gemcitabine&nbsp;plus&nbsp;Paclitaxel&nbsp;arm&nbsp;(N=262)</p></td></tr><tr><td><p>Grade&nbsp;3</p></td><td><p>Grade&nbsp;4</p></td><td><p>Grade&nbsp;3</p></td><td><p>Grade&nbsp;4</p></td></tr><tr><td><p>Laboratory</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Anaemia</p></td><td><p>5&nbsp;(1.9)</p></td><td><p>1&nbsp;(0.4)</p></td><td><p>15&nbsp;(5.7)</p></td><td><p>3&nbsp;(1.1)</p></td></tr><tr><td><p>Thrombocytopaenia</p></td><td><p>0</p></td><td><p>0</p></td><td><p>14&nbsp;(5.3)</p></td><td><p>1&nbsp;(0.4)</p></td></tr><tr><td><p>Neutropaenia</p></td><td><p>11&nbsp;(4.2)</p></td><td><p>17&nbsp;(6.6)*</p></td><td><p>82&nbsp;(31.3)</p></td><td><p>45&nbsp;(17.2)*</p></td></tr><tr><td><p>Non-laboratory</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Febrile&nbsp;neutropaenia</p></td><td><p>3&nbsp;(1.2)</p></td><td><p>0</p></td><td><p>12&nbsp;(4.6)</p></td><td><p>1(0.4)</p></td></tr><tr><td><p>Fatigue</p></td><td><p>3&nbsp;(1.2)</p></td><td><p>1&nbsp;(0.4)</p></td><td><p>15&nbsp;(5.7)</p></td><td><p>2&nbsp;(0.8)</p></td></tr><tr><td><p>Diarrhoea</p></td><td><p>5&nbsp;(1.9)</p></td><td><p>0</p></td><td><p>8&nbsp;(3.1)</p></td><td><p>0</p></td></tr></tbody></table><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>Motor&nbsp;neuropathy</p></td><td><p>2(0.8)</p></td><td><p>0</p></td><td><p>6(2.3)</p></td><td><p>1(0.4)</p></td></tr><tr><td><p>Sensory&nbsp;neuropathy</p></td><td><p>9(3.5)</p></td><td><p>0</p></td><td><p>14(5.3)</p></td><td><p>1(0.4)</p></td></tr></tbody></table><p>*Grade&nbsp;4&nbsp;neutropaenia&nbsp;lasting&nbsp;for&nbsp;more&nbsp;than&nbsp;7&nbsp;days&nbsp;occurred&nbsp;in&nbsp;12.6%&nbsp;of&nbsp;patients&nbsp;in&nbsp;the&nbsp;combination&nbsp;arm and 5.0% of patients in the paclitaxel arm.</p><p><em>Combination&nbsp;use&nbsp;in&nbsp;bladder&nbsp;cancer</em></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="5"><p>Grade 3 and 4 Adverse Events MVAC&nbsp;versus&nbsp;Gemcitabine&nbsp;plus&nbsp;cisplatin</p></td></tr><tr><td rowspan="3"><p>&nbsp;</p></td><td colspan="4"><p>Number&nbsp;(%)&nbsp;of&nbsp;Patients</p></td></tr><tr><td colspan="2"><p>MVAC&nbsp;(methotrexate,&nbsp;vinblastine, doxorubicin and cisplatin) arm&nbsp;(N=196)</p></td><td colspan="2"><p>Gemcitabine&nbsp;plus&nbsp;cisplatin&nbsp;arm&nbsp;(N=200)</p></td></tr><tr><td><p>Grade&nbsp;3</p></td><td><p>Grade&nbsp;4</p></td><td><p>Grade&nbsp;3</p></td><td><p>Grade&nbsp;4</p></td></tr><tr><td><p>Laboratory</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Anaemia</p></td><td><p>30(16)</p></td><td><p>4(2)</p></td><td><p>47(24)</p></td><td><p>7(4)</p></td></tr><tr><td><p>Thrombocytopaenia</p></td><td><p>15(8)</p></td><td><p>25(13)</p></td><td><p>57(29)</p></td><td><p>57(29)</p></td></tr><tr><td><p>Non-laboratory</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Nausea&nbsp;and&nbsp;vomiting</p></td><td><p>37(19)</p></td><td><p>3(2)</p></td><td><p>44(22)</p></td><td><p>0(0)</p></td></tr><tr><td><p>Diarrhoea</p></td><td><p>15(8)</p></td><td><p>1(1)</p></td><td><p>6(3)</p></td><td><p>0(0)</p></td></tr><tr><td><p>Infection</p></td><td><p>19(10)</p></td><td><p>10(5)</p></td><td><p>4(2)</p></td><td><p>1(1)</p></td></tr><tr><td><p>Stomatitis</p></td><td><p>34(18)</p></td><td><p>8(4)</p></td><td><p>2(1)</p></td><td><p>0(0)</p></td></tr></tbody></table><p>&nbsp;</p><p><em>Combination&nbsp;use&nbsp;in&nbsp;ovarian&nbsp;cancer</em></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="5"><p>Grade 3 and 4 Adverse Events Carboplatin&nbsp;versus&nbsp;Gemcitabine&nbsp;plus&nbsp;carboplatin</p></td></tr><tr><td rowspan="3"><p>&nbsp;</p></td><td colspan="4"><p>Number&nbsp;(%)&nbsp;of&nbsp;Patients</p></td></tr><tr><td colspan="2"><p>Carboplatin&nbsp;arm&nbsp;(N=174)</p></td><td colspan="2"><p>Gemcitabine&nbsp;plus&nbsp;carboplatin&nbsp;arm&nbsp;(N=175)</p></td></tr><tr><td><p>Grade&nbsp;3</p></td><td><p>Grade&nbsp;4</p></td><td><p>Grade&nbsp;3</p></td><td><p>Grade&nbsp;4</p></td></tr><tr><td><p>Laboratory</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Anaemia</p></td><td><p>10(5.7)</p></td><td><p>4(2.3)</p></td><td><p>39(22.3)</p></td><td><p>9(5.1)</p></td></tr><tr><td><p>Neutropaenia</p></td><td><p>19(10.9)</p></td><td><p>2(1.1)</p></td><td><p>73(41.7)</p></td><td><p>50(28.6)</p></td></tr><tr><td><p>Thrombocytopaenia</p></td><td><p>18(10.3)</p></td><td><p>2(1.1)</p></td><td><p>53(30.3)</p></td><td><p>8(4.6)</p></td></tr><tr><td><p>Leucopaenia</p></td><td><p>11(6.3)</p></td><td><p>1(0.6)</p></td><td><p>84(48.0)</p></td><td><p>9(5.1)</p></td></tr><tr><td><p>Non-laboratory</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Haemorrhage</p></td><td><p>0(0.0)</p></td><td><p>0(0.0)</p></td><td><p>3(1.8)</p></td><td><p>(0.0)</p></td></tr><tr><td><p>Febrile&nbsp;neutropaenia</p></td><td><p>0(0.0)</p></td><td><p>0(0.0)</p></td><td><p>2(1.1)</p></td><td><p>(0.0)</p></td></tr><tr><td><p>Infection&nbsp;without&nbsp;neutropaenia</p></td><td><p>0(0)</p></td><td><p>0(0.0)</p></td><td><p>(0.0)</p></td><td><p>1(0.6)</p></td></tr></tbody></table><p>&nbsp;</p><p>Sensory&nbsp;neuropathy&nbsp;was&nbsp;also&nbsp;more&nbsp;frequent&nbsp;in&nbsp;the&nbsp;combination&nbsp;arm&nbsp;than&nbsp;with&nbsp;single&nbsp;agent&nbsp;Carboplatin</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]--><strong>Saudi&nbsp;Arabia:</strong></p><p>The&nbsp;National&nbsp;Pharmacovigilance&nbsp;and&nbsp;Drug&nbsp;Safety&nbsp;Centre&nbsp;(NPC).</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->Fax:&nbsp;+966-11-2057662</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->Call&nbsp;NPC&nbsp;at&nbsp;+966-11-2038222,&nbsp;Exts:&nbsp;2317-2356-2353-2354-2334-2340.</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->Toll&nbsp;free&nbsp;phone:&nbsp;8002490000</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->E-mail:&nbsp;npc.drug@sfda.gov.sa</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->Website:&nbsp;www.sfda.gov.sa/npc</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]--><strong>Other&nbsp;GCC&nbsp;States:</strong></p><p>Please&nbsp;contact&nbsp;the&nbsp;relevant&nbsp;competent&nbsp;authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There is&nbsp;no&nbsp;known&nbsp;antidote for&nbsp;overdose of&nbsp;gemcitabine.&nbsp;Doses&nbsp;as&nbsp;high&nbsp;as&nbsp;5700&nbsp;mg/m2&nbsp;have beenadministered by intravenous&nbsp;infusion over 30&nbsp;minutes every 2&nbsp;weeks with clinically acceptable&nbsp;toxicity. In&nbsp;the&nbsp;event&nbsp;of&nbsp;suspected&nbsp;overdose,&nbsp;the&nbsp;patient&nbsp;should&nbsp;be&nbsp;monitored&nbsp;with appropriate blood counts and receive supportive&nbsp;therapy, as necessary.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic&nbsp;group:&nbsp;pyrimidine&nbsp;analogues&nbsp;ATC&nbsp;code:&nbsp;L01BC05&nbsp;<u>Mechanism of action</u></p><p>Cellular&nbsp;metabolism&nbsp;and&nbsp;mechanism&nbsp;of&nbsp;action:&nbsp;Gemcitabine&nbsp;(dFdC),which&nbsp;is&nbsp;a&nbsp;pyrimidine</p><p>antimetabolite,&nbsp;is&nbsp;metabolised intracellularly by&nbsp;nucleoside kinase to&nbsp;the&nbsp;active diphosphate (dFdCDP) andtriphosphate&nbsp;(dFdCTP) nucleosides.&nbsp;The cytotoxic effect of gemcitabine&nbsp;is due to inhibition&nbsp;of&nbsp;DNA synthesis by&nbsp;two&nbsp;mechanisms&nbsp;of&nbsp;action&nbsp;by&nbsp;dFdCDP&nbsp;and&nbsp;dFdCTP. First,&nbsp;dFdCDP inhibits ribonucleotide reductase,&nbsp;whichis&nbsp;uniquely&nbsp;responsible for catalysing the reactions that produce deoxynucleoside triphosphates&nbsp;(dCTP) forDNA synthesis. Inhibition of&nbsp;this enzyme by dFdCDP reduces&nbsp;the&nbsp;concentration&nbsp;of&nbsp;deoxynucleosides&nbsp;in&nbsp;generaland,&nbsp;in&nbsp;particular,&nbsp;dCTP.&nbsp;Second, dFdCTP&nbsp;competes with dCTP for incorporation&nbsp;into DNA (self-potentiation).</p><p>&nbsp;</p><p>Likewise,&nbsp;a small&nbsp;amount of gemcitabine&nbsp;may also be incorporated into RNA. Thus, the reduced intracellularconcentration of dCTP potentiates the incorporation of dFdCTP&nbsp;into&nbsp;DNA.&nbsp;DNA polymerase epsilon lacks the ability to&nbsp;eliminate gemcitabine&nbsp;and&nbsp;to&nbsp;repair the growing DNA strands. After gemcitabine&nbsp;is incorporated intoDNA,&nbsp;one additional&nbsp;nucleotide is added to&nbsp;the growing DNA strands. After&nbsp;this&nbsp;addition&nbsp;there&nbsp;is&nbsp;essentially&nbsp;acomplete inhibition in&nbsp;further&nbsp;DNA&nbsp;synthesis (masked chain&nbsp;termination).&nbsp;After&nbsp;incorporation&nbsp;into&nbsp;DNA,gemcitabine&nbsp;appears&nbsp;to&nbsp;induce&nbsp;the&nbsp;programmed&nbsp;cell death process known as apoptosis.</p><p>&nbsp;</p><p><u>Pharmacodynamic&nbsp;effects</u></p><p><em>Cytotoxic&nbsp;activity&nbsp;in&nbsp;cell&nbsp;cultures</em></p><p>Gemcitabine&nbsp;shows significant cytotoxic effects&nbsp;against a variety of cultured murine and&nbsp;human tumour cells. Its action is phase-specific&nbsp;such&nbsp;that gemcitabine&nbsp;primarily kills cells that are undergoing&nbsp;DNA&nbsp;synthesis (Sphase)&nbsp;and,&nbsp;under&nbsp;certain&nbsp;circumstances,&nbsp;blocks&nbsp;the&nbsp;progression&nbsp;of&nbsp;cells at&nbsp;the junction of the G1/S&nbsp;phase boundary. In&nbsp;vitro,&nbsp;the cytotoxic effect of gemcitabine&nbsp;is dependent on both concentration and time.</p><p>&nbsp;</p><p><em>Antitumoral&nbsp;activity&nbsp;in&nbsp;preclinical&nbsp;models</em></p><p>In&nbsp;animal&nbsp;tumour models,antitumoural activity of gemcitabine&nbsp;is schedule&nbsp;-dependent.&nbsp;When&nbsp;gemcitabine&nbsp;is administered daily,&nbsp;high&nbsp;mortality&nbsp;among the animals but&nbsp;minimal&nbsp;antitumoural&nbsp;activity&nbsp;is&nbsp;observed.&nbsp;If,&nbsp;however,&nbsp;gemcitabine&nbsp;is&nbsp;given&nbsp;every&nbsp;third&nbsp;or&nbsp;fourth&nbsp;day,&nbsp;it&nbsp;can&nbsp;be&nbsp;administered&nbsp;in&nbsp;non-lethal&nbsp;doses&nbsp;with&nbsp;substantia&nbsp;l&nbsp;antitumoura&nbsp;l&nbsp;activity&nbsp;against&nbsp;a&nbsp;broad&nbsp;spectrum&nbsp;of&nbsp;mouse&nbsp;tumors.</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Clinical&nbsp;efficacy&nbsp;and&nbsp;safety</u></p><p><em>Bladder&nbsp;cancer</em></p><p>A&nbsp;randomised&nbsp;phase III&nbsp;study&nbsp;of&nbsp;405&nbsp;patients with&nbsp;advanced&nbsp;or&nbsp;metastatic urothelial&nbsp;transitional&nbsp;cell carcinoma showed no&nbsp;difference between the two treatment arms, gemcitabine/cisplatin&nbsp;versus methotrexate/vinblastine/adriamyc in/cisplatin&nbsp;(MVAC),&nbsp;in&nbsp;terms&nbsp;of&nbsp;median&nbsp;survival&nbsp;(12.8&nbsp;and&nbsp;14.8 months respectively, p&nbsp;=&nbsp;0.547),&nbsp;time to&nbsp;disease progression (7.4 and 7.6 months respective&nbsp;ly,</p><p>p&nbsp;=&nbsp;0.842)&nbsp;and&nbsp;response rate&nbsp;(49.4%&nbsp;and&nbsp;45.7% respectively,&nbsp;p&nbsp;=&nbsp;0.512). However,&nbsp;the&nbsp;combination of gemcitabine&nbsp;and cisplatin had a better toxicity profile than MVAC.</p><p><em>Pancreatic&nbsp;cancer</em></p><p>In&nbsp;a randomised phase III&nbsp;study of 126 patients with advanced or metastatic&nbsp;pancreatic&nbsp;cancer, gemcitabineshowed&nbsp;a&nbsp;statistically significant&nbsp;higher clinical&nbsp;benefit response rate&nbsp;than&nbsp;5-fluorouracil (23.8% and&nbsp;4.8%respectively,&nbsp;p&nbsp;=&nbsp;0.0022). Also,&nbsp;a&nbsp;statistically significant&nbsp;prolongation of&nbsp;the&nbsp;time to progression from&nbsp;0.9&nbsp;to&nbsp;2.3months (log-rank&nbsp;p&lt;&nbsp;0.0002) and&nbsp;a&nbsp;statistically significant&nbsp;prolongation of median survival&nbsp;from 4.4 to&nbsp;5.7 months (log-rank p&lt;&nbsp;0.0024) was observed in&nbsp;patients treated with gemcitabine&nbsp;compared to patients treatedwith 5-fluorouracil.</p><p><em>Non&nbsp;small&nbsp;cell&nbsp;lung&nbsp;cancer</em></p><p>In&nbsp;a randomised phase III&nbsp;study of 522 patients with inoperable,&nbsp;locally advanced or metastatic NSCLC,gemcitabine&nbsp;in&nbsp;combination&nbsp;with&nbsp;cisplatin&nbsp;showed&nbsp;a&nbsp;statistically&nbsp;significant&nbsp;higher&nbsp;response rate than&nbsp;cisplatin alone (31.0%&nbsp;and&nbsp;12.0%,&nbsp;respective&nbsp;ly,&nbsp;p&lt;&nbsp;0.0001). A statistically significant prolongation of the time to progression, from 3.7 to&nbsp;5.6 months (log-rank p&lt; 0.0012) and a statistically significant prolongation of median survival&nbsp;from&nbsp;7.6 months to&nbsp;9.1 months (log-rank</p><p>p&lt;&nbsp;0.004)&nbsp;was&nbsp;observed&nbsp;in&nbsp;patients treated&nbsp;with&nbsp;gemcitabine/cisplatin&nbsp;compared&nbsp;to&nbsp;patients treated&nbsp;with cisplatin. In another randomised phase III study of 135 patients with stage IIIB&nbsp;or IV&nbsp;NSCLC,&nbsp;a combination of gemcitabine and&nbsp;cisplatin showed a statistically signifcant higher response rate than&nbsp;a combination of cisplatin and&nbsp;etoposide (40.6% and&nbsp;21.2%, respectively, p&nbsp;=&nbsp;0.025). A statistically significant prolongation of the time toprogression, from 4.3 to&nbsp;6.9 months (p =&nbsp;0.014) was observed&nbsp;in&nbsp;patients&nbsp;treated&nbsp;with&nbsp;gemcitabine/cisplatin&nbsp;compared&nbsp;to&nbsp;patients&nbsp;treated&nbsp;with&nbsp;etoposide/cisplatin.&nbsp;In both studies it was found that tolerability was similar in&nbsp;the two treatment arms.</p><p>&nbsp;</p><p><em>Ovarian&nbsp;carcinoma</em></p><p>In&nbsp;a randomised phase III&nbsp;study,&nbsp;356&nbsp;patients with advanced epithelial&nbsp;ovarian&nbsp;carcinoma&nbsp;who had relapsed at least&nbsp;6&nbsp;months after&nbsp;completing platinum based therapy were randomised to&nbsp;therapy with gemcitabine&nbsp;andcarboplatin&nbsp;(GCb),&nbsp;or&nbsp;carboplatin (Cb). A&nbsp;statistically significant&nbsp;prolongation of&nbsp;the time to&nbsp;progression of disease, from 5.8 to&nbsp;8.6 months (log-rank p&nbsp;=&nbsp;0.0038) was observed in&nbsp;the patients treated&nbsp;with&nbsp;GCb&nbsp;compared to&nbsp;patients treated&nbsp;with&nbsp;Cb. Differences&nbsp;in&nbsp;response&nbsp;rate of&nbsp;47.2% in&nbsp;the GCb arm&nbsp;versus&nbsp;30.9%&nbsp;in&nbsp;the Cb&nbsp;arm&nbsp;(p=&nbsp;0.0016)&nbsp;and median survival&nbsp;18&nbsp;months&nbsp;(GCb) versus 17.3 (Cb) (p = 0.73) favoured the GCb&nbsp;arm.</p><p>&nbsp;</p><p><em>Breast&nbsp;cancer</em></p><p>In&nbsp;a&nbsp;randomised phase III&nbsp;study&nbsp;of&nbsp;529&nbsp;patients with inoperable,&nbsp;locally recurrent or&nbsp;metastatic&nbsp;breast cancer with&nbsp;relapse after&nbsp;adjuvant/neoadjuvant&nbsp;chemotherapy, gemcitabine in&nbsp;combination with paclitaxel&nbsp;showed a statistically significant prolongation of time to&nbsp;documented disease progression from&nbsp;3.98 to&nbsp;6.14 months (log-rank p&nbsp;=&nbsp;0.0002)&nbsp;in&nbsp;patients treated with gemcitabine/paclitaxel compared to&nbsp;patients treated with paclitaxel.After 377&nbsp;deaths, the overall&nbsp;survival&nbsp;was 18.6 months versus 15.8 months (log rank p&nbsp;=&nbsp;0.0489, HR 0.82) inpatients treated with gemcitabine/paclitaxel compared to&nbsp;patients treated with paclitaxel and the overallresponse rate was 41.4% and 26.2% respectively (p = 0.0002).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The pharmacokinetics&nbsp;of gemcitabine&nbsp;have been&nbsp;examined in&nbsp;353&nbsp;patients&nbsp;in&nbsp;seven studies. The 121 womenand&nbsp;232&nbsp;men&nbsp;ranged&nbsp;in&nbsp;age from&nbsp;29&nbsp;to&nbsp;79&nbsp;years. Of&nbsp;these&nbsp;patients,&nbsp;approximately&nbsp;45% had&nbsp;non</p><p>small&nbsp;cell&nbsp;lung&nbsp;cancer&nbsp;and&nbsp;35%&nbsp;were diagnosed&nbsp;with&nbsp;pancreatic&nbsp;cancer.&nbsp;The&nbsp;following2</p><p>pharmacokinetic&nbsp;parameters&nbsp;were obtained&nbsp;for&nbsp;doses ranging&nbsp;from&nbsp;500&nbsp;to&nbsp;2,592&nbsp;mg/m&nbsp;that&nbsp;were infused from 0.4 to 1.2 hours.</p><p>&nbsp;</p><p><u>Absorption</u></p><p>Peak&nbsp;plasma&nbsp;concentrations&nbsp;(obtained&nbsp;within&nbsp;5&nbsp;minutes&nbsp;of&nbsp;the&nbsp;end&nbsp;of&nbsp;the&nbsp;infusion)&nbsp;were&nbsp;3.2&nbsp;to</p><p>45.5 &micro;g/ml. Plasma concentrations of the parent compound following a dose of 1,000 mg/m2/30 minutes are greater than 5 &micro;g/ml&nbsp;for approximately 30&nbsp;minutes after the end of the infusion,&nbsp;and greater than 0.4 &micro;g/ml for an additional hour.</p><p>&nbsp;</p><p><u>Distribution</u></p><p>The volume of distribution of the central&nbsp;compartment&nbsp;was 12.4 l/m2&nbsp;for women and&nbsp;17.5 l/m2&nbsp;for men&nbsp;(inter individua&nbsp;l&nbsp;variability was 91.9%). The volume of distribution of the peripheral compartment was 47.4&nbsp;l/&nbsp;m2. The volume of the peripheral&nbsp;compartment was not sensitive to&nbsp;gender. The plasma protein binding wasconsidered to&nbsp;be&nbsp;negligible.&nbsp;Half life&nbsp;:&nbsp;This ranged from 42 to&nbsp;94 minutes&nbsp;depending&nbsp;on&nbsp;age&nbsp;and&nbsp;gender.&nbsp;For&nbsp;therecommended dosing&nbsp;schedule&nbsp;,&nbsp;gemcitabine&nbsp;elimination should be virtually&nbsp;complete within 5&nbsp;to&nbsp;11&nbsp;hours of the start&nbsp;of the infusion. Gemcitabine&nbsp;does not accumulate&nbsp;when administered&nbsp;once weekly.</p><p><u>Biotransformation</u></p><p>Gemcitabine&nbsp;is rapidly metabolised by&nbsp;cytidine deaminase&nbsp;in&nbsp;the&nbsp;liver,&nbsp;kidney,&nbsp;blood and&nbsp;other tissues.Intracellular&nbsp;metabolism&nbsp;of&nbsp;gemcitabine&nbsp;produces&nbsp;the&nbsp;gemcitabine&nbsp;mono,&nbsp;di&nbsp;and&nbsp;triphosphates (dFdCMP, dFdCDP&nbsp;and dFdCTP) of which dFdCDP and dFdCTP&nbsp;are&nbsp;considered active. These intracellular metabolites have not&nbsp;been&nbsp;detected&nbsp;in&nbsp;plasma or&nbsp;urine. The primary&nbsp;metabolite,&nbsp;2&#39;&nbsp;deoxy 2&#39;,&nbsp;2&#39; difluorouridine (dFdU), is not active and is found in&nbsp;plasma and&nbsp;urine.</p><p>&nbsp;</p><p><u>Elimination</u></p><p>Systemic clearance ranged from 29.2 l/hr/m2&nbsp;to&nbsp;92.2 /hr/m2&nbsp;depending on gender and age (inter individua&nbsp;lvariability&nbsp;was&nbsp;52.2%).&nbsp;Clearance&nbsp;for&nbsp;women&nbsp;is&nbsp;approximately&nbsp;25%&nbsp;lower&nbsp;than&nbsp;the&nbsp;values for men. Although rapid, clearance for both men and&nbsp;women appears to&nbsp;decrease with age.&nbsp;For the recommended gemcitabinedose of 1000 mg/m2&nbsp;given as a&nbsp;30&nbsp;minute infusion, lower clearance values&nbsp;for women and men should not necessitate a decrease in&nbsp;the gemcitabine&nbsp;dose.</p><p>Urinary&nbsp;excretion:&nbsp;Less&nbsp;than&nbsp;10%&nbsp;is&nbsp;excreted&nbsp;as&nbsp;unchanged&nbsp;drug.&nbsp;Renal&nbsp;clearance&nbsp;was&nbsp;2&nbsp;to&nbsp;7&nbsp;l/hr/m2.</p><p>&nbsp;</p><p><strong>During the week&nbsp;following&nbsp;administration, 92&nbsp;to&nbsp;98% of the dose of gemcitabine&nbsp;administered is recovered, 99% in&nbsp;the urine,&nbsp;mainly&nbsp;in&nbsp;the form&nbsp;of&nbsp;dFdU and&nbsp;1% of&nbsp;the dose&nbsp;is&nbsp;excreted in&nbsp;faeces.</strong></p><p><em>dFdCTP&nbsp;kinetics</em></p><p>This&nbsp;metabolite&nbsp;can&nbsp;be&nbsp;found&nbsp;in&nbsp;peripheral&nbsp;blood mononuclear&nbsp;cells&nbsp;and&nbsp;the&nbsp;information&nbsp;below&nbsp;refers to&nbsp;thesecells. Intracellular concentrations&nbsp;increase in&nbsp;proportion to&nbsp;gemcitabine&nbsp;doses of</p><p>35-350&nbsp;mg/m2/30&nbsp;minutes,&nbsp;which&nbsp;give&nbsp;steady&nbsp;state&nbsp;concentrations&nbsp;of&nbsp;0.4-5&nbsp;&micro;g/ml.&nbsp;At&nbsp;gemcitabine</p><p>plasma&nbsp;concentrations&nbsp;above&nbsp;5&nbsp;&micro;g/ml,&nbsp;dFdCTP&nbsp;levels&nbsp;do&nbsp;not&nbsp;increase,&nbsp;suggesting&nbsp;that&nbsp;the&nbsp;formation&nbsp;is saturablein&nbsp;these cells. Half life of terminal&nbsp;elimination: 0.7-12 hours.</p><p>&nbsp;</p><p><em>dFdU&nbsp;kinetics</em></p><p>Peak&nbsp;plasma&nbsp;concentrations&nbsp;(3-15&nbsp;minutes&nbsp;after&nbsp;end&nbsp;of&nbsp;30&nbsp;minute&nbsp;infusion,&nbsp;1000&nbsp;mg/m2):</p><p>28-52&nbsp;&micro;g/ml.&nbsp;Trough&nbsp;concentration&nbsp;following&nbsp;once&nbsp;weekly&nbsp;dosing:&nbsp;0.07-1.12&nbsp;&micro;g/ml,&nbsp;with&nbsp;no&nbsp;apparent accumulation.&nbsp;Triphasic plasma concentration versus time curve,&nbsp;mean&nbsp;half life of terminal&nbsp;phase</p><p>65&nbsp;hours&nbsp;(range&nbsp;33-84&nbsp;hr).</p><p>Formation&nbsp;of&nbsp;dFdU&nbsp;from&nbsp;parent&nbsp;compound:&nbsp;91%&nbsp;-98%. &nbsp; &nbsp;&nbsp;</p><p>Mean&nbsp;volume&nbsp;of&nbsp;distribution&nbsp;of&nbsp;central&nbsp;compartment:&nbsp;18&nbsp;l/m&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(range&nbsp;11-22&nbsp;l/m&nbsp;).</p><p>Mean&nbsp;steady&nbsp;state&nbsp;volume of&nbsp;distribution&nbsp;(Vss):&nbsp;150&nbsp;l/m2&nbsp;(range&nbsp;96-228 l/m2). Tissue distribution: Extensive.</p><p>Mean&nbsp;apparent&nbsp;clearance:&nbsp;2.5&nbsp;l/hr/m2&nbsp;(range&nbsp;1-4&nbsp;l/hr/m2).</p><p>Urinary&nbsp;excretion:&nbsp;All.</p><p>&nbsp;</p><p><em>Gemcitabine&nbsp;and paclitaxel&nbsp;combination&nbsp;therapy</em></p><p>Combination&nbsp;therapy&nbsp;did&nbsp;not&nbsp;alter&nbsp;the&nbsp;pharmacokinetics&nbsp;of&nbsp;either&nbsp;gemcitabine&nbsp;or&nbsp;paclitaxel.</p><p>&nbsp;</p><p><em>Gemcitabine&nbsp;and&nbsp;carboplatin&nbsp;combination&nbsp;therapy</em></p><p>When&nbsp;given&nbsp;in&nbsp;combination&nbsp;with&nbsp;carboplatin&nbsp;the&nbsp;pharmacokinetics&nbsp;of&nbsp;gemcitabine&nbsp;were&nbsp;not&nbsp;altered</p><p>&nbsp;</p><p><em>Renal&nbsp;impairment</em></p><p>Mild&nbsp;to&nbsp;moderate&nbsp;renal&nbsp;insufficiency&nbsp;(GFR from&nbsp;30&nbsp;ml/min&nbsp;to&nbsp;80&nbsp;ml/min) has&nbsp;no&nbsp;consistent, significant effect on gemcitabine&nbsp;pharmacokinetics.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In&nbsp;repeat&nbsp;dose studies of&nbsp;up&nbsp;to&nbsp;6&nbsp;months&nbsp;in&nbsp;duration&nbsp;in&nbsp;mice and&nbsp;dogs,&nbsp;the principal&nbsp;finding&nbsp;was schedule and dose-dependent&nbsp;haematopoietic&nbsp;suppression which was reversible.</p><p>Gemcitabine&nbsp;is&nbsp;mutagenic&nbsp;in&nbsp;an&nbsp;in&nbsp;vitro&nbsp;mutation&nbsp;test&nbsp;and&nbsp;an&nbsp;in&nbsp;vivo&nbsp;bone&nbsp;marrow micronucleus&nbsp;test. Long term animal&nbsp;studies evaluating the carcinogenic&nbsp;potential&nbsp;have not been performed.</p><p>In&nbsp;fertility&nbsp;studies,&nbsp;gemcitabine&nbsp;caused&nbsp;reversible&nbsp;hypospermatogenesis&nbsp;in&nbsp;male&nbsp;mice.&nbsp;No&nbsp;effect&nbsp;on&nbsp;the fertility of females has been detected.</p><p>Evaluation&nbsp;of&nbsp;experimental&nbsp;animal&nbsp;studies&nbsp;has&nbsp;shown&nbsp;reproductive&nbsp;toxicity&nbsp;e.g.&nbsp;birth&nbsp;defects&nbsp;and&nbsp;other effects onthe development of the embryo or foetus, the course of gestation or peri- and&nbsp;postnatal&nbsp;development.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Mannitol&nbsp;E421</p><p>Sodium&nbsp;acetate&nbsp;trihydrate</p><p>Sodium&nbsp;hydroxide&nbsp;1&nbsp;N&nbsp;(for&nbsp;pH&nbsp;adjustment)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>This&nbsp;medicinal&nbsp;product&nbsp;must&nbsp;not&nbsp;be&nbsp;mixed&nbsp;with&nbsp;other&nbsp;medicinal&nbsp;products&nbsp;except&nbsp;those&nbsp;mentioned&nbsp;in section 6.6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Powder
3 years.

Reconstituted solution
Chemical and physical in-use stability has been demonstrated for 24 hours at 25°C. From a microbiological point of view, the product should be used immediately. If not used immediately, in- use storage times and conditions prior to use are the responsibility of the user. Solutions of reconstituted gemcitabine should not be refrigerated, as crystallisation may occur.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do&nbsp;not&nbsp;refrigerate&nbsp;or&nbsp;freeze.</p><p>For&nbsp;storage&nbsp;conditions&nbsp;after&nbsp;reconstitution&nbsp;of&nbsp;the&nbsp;medicinal&nbsp;product,&nbsp;see&nbsp;section&nbsp;6.3.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Citarox is&nbsp;packed in&nbsp;colourless glass vials&nbsp;(type I)&nbsp;with bromobutylic&nbsp;rubber stopper and&nbsp;sealed&nbsp;with aluminiumseals&nbsp;with&nbsp;polypropylene&nbsp;caps.&nbsp;The&nbsp;vial&nbsp;will&nbsp;be&nbsp;packed&nbsp;with&nbsp;or&nbsp;without&nbsp;a&nbsp;protective&nbsp;plastic&nbsp;overwrap.</p><p>&nbsp;</p><p><em>Pack&nbsp;sizes</em></p><p>One&nbsp;vial&nbsp;containing&nbsp;200&nbsp;mg&nbsp;gemcitabine. One vial containing 1 g gemcitabine.</p><p>One&nbsp;vial&nbsp;containing&nbsp;2&nbsp;g&nbsp;gemcitabine.</p><p>&nbsp;</p><p>Not&nbsp;all&nbsp;pack&nbsp;sizes&nbsp;may&nbsp;be&nbsp;marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Handling</u></p><p>The&nbsp;normal&nbsp;safety&nbsp;precautions for&nbsp;cytostatic agents&nbsp;must&nbsp;be&nbsp;observed&nbsp;when&nbsp;preparing&nbsp;and&nbsp;disposing of the infusion&nbsp;solution.&nbsp;Handling of the solution for infusion&nbsp;should be done&nbsp;in&nbsp;a safety box&nbsp;and protective&nbsp;coats and&nbsp;gloves should be used. If no&nbsp;safety box&nbsp;is available, the equipment should be&nbsp;supplemented&nbsp;with&nbsp;a&nbsp;mask&nbsp;and&nbsp;protective&nbsp;glasses. If&nbsp;the&nbsp;preparation&nbsp;comes&nbsp;into&nbsp;contact&nbsp;with&nbsp;the eyes,&nbsp;this may cause serious irritation. The eyes&nbsp;should be rinsed immediately and&nbsp;thoroughly with&nbsp;water. If&nbsp;there is&nbsp;lasting&nbsp;irritation,&nbsp;a&nbsp;doctorshould&nbsp;be&nbsp;consulted. If&nbsp;the&nbsp;solution is&nbsp;spilled&nbsp;on the skin, rinse thoroughly with water.</p><p>&nbsp;</p><p><u>Instructions&nbsp;for&nbsp;reconstitution&nbsp;(and&nbsp;further&nbsp;dilution,&nbsp;if&nbsp;performed)</u></p><p>The&nbsp;only&nbsp;approved&nbsp;diluent&nbsp;for&nbsp;reconstitution&nbsp;of&nbsp;gemcitabine&nbsp;sterile&nbsp;powder&nbsp;is&nbsp;sodium&nbsp;chloride 9&nbsp;mg/ml&nbsp;(0.9%)solution&nbsp;for&nbsp;injection&nbsp;(without&nbsp;preservative).&nbsp;Due&nbsp;to&nbsp;solubility&nbsp;considerations</p><p>,&nbsp;the&nbsp;maximum&nbsp;concentration&nbsp;for&nbsp;gemcitabine&nbsp;upon&nbsp;reconstitution&nbsp;is&nbsp;40&nbsp;mg/ml.&nbsp;Reconstitution at&nbsp;concentrationsgreater than 40&nbsp;mg/ml&nbsp;may result&nbsp;in&nbsp;incomplete&nbsp;dissolution and&nbsp;should be&nbsp;avoided.</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->Use&nbsp;aseptic&nbsp;technique during&nbsp;the&nbsp;reconstitution&nbsp;and&nbsp;any&nbsp;further&nbsp;dilution of gemcitabine&nbsp;for intravenous&nbsp;infusion administration.</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->To&nbsp;reconstitute,&nbsp;add&nbsp;the&nbsp;appropriate&nbsp;volume of&nbsp;sterile sodium&nbsp;chloride&nbsp;9&nbsp;mg/ml&nbsp;(0.9%) solution&nbsp;forinjection without preservative&nbsp;(as&nbsp;stated&nbsp;in&nbsp;the table below) and&nbsp;shake to&nbsp;dissolve:</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>Presentation</p></td><td><p>Volume&nbsp;of&nbsp;sterile</p><p>sodium&nbsp;chloride&nbsp;9</p><p>mg/ml&nbsp;(0.9%)&nbsp;solution&nbsp;for injection (without preservative)&nbsp;to be&nbsp;added</p></td><td><p>Total&nbsp;volume&nbsp;after</p><p>reconstitution</p></td><td><p>Final&nbsp;concentration</p></td></tr><tr><td><p>200&nbsp;mg</p></td><td><p>5&nbsp;ml</p></td><td><p>5.26&nbsp;ml</p></td><td><p>38&nbsp;mg/ml</p></td></tr><tr><td><p>1&nbsp;g</p></td><td><p>25&nbsp;ml</p></td><td><p>26.3&nbsp;ml</p></td><td><p>38&nbsp;mg/ml</p></td></tr><tr><td><p>2&nbsp;g</p></td><td><p>50&nbsp;ml</p></td><td><p>52.6&nbsp;ml</p></td><td><p>38&nbsp;mg/ml</p></td></tr></tbody></table><p>Further dilution with sterile sodium chloride 9 mg/ml (0.9 %) solution for injection, without preservative can be done. Reconstituted solution is a clear colourless to light straw-coloured solution.</p><p><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->Parenteral&nbsp;medicinal&nbsp;products&nbsp;should&nbsp;be&nbsp;inspected&nbsp;visually&nbsp;for&nbsp;particulate&nbsp;matter&nbsp;and discolouration prior to&nbsp;administration.&nbsp;If particulate&nbsp;matter is observed, do&nbsp;not&nbsp;administer.</p><p>Any&nbsp;unused&nbsp;medicinal&nbsp;product&nbsp;or&nbsp;waste material&nbsp;should&nbsp;be&nbsp;disposed&nbsp;of&nbsp;in&nbsp;accordance&nbsp;with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                HOLDER Tadawi Biomedical company
Olaya st,
Riyadh 
Saudi Arabia

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                10/2017
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>